March 2022

NCDR®

NATIONAL CARDIOVASCULAR DATA REGISTRY

Published Manuscripts Based on NCDR Registries

NCDR®
NATIONAL CARDIOVASCULAR DATA REGISTRY

Published Registry Manuscripts Table of Contents (TOC)

Legend

Manuscript Status is designated as follows:

- Published/Full Citation Provided: Manuscript is in print.
- In Press: Manuscript accepted for publication but has not yet appeared in print or on-line.

Abbreviations:

- Am J Cardiol: American Journal of Cardiology
- Am J Emerg Med: American Journal of Emergency Medicine
- Am J Medicine: American Journal of Medicine
- Am Heart J: American Heart Journal
- Br Med J: British Medical Journal
- Catheter Cardiovasc Interv: Catheterization and Cardiovascular Interventions.
- Circulation: Circulation
- Circ Arrythm Electrophysiol: Circulation: Arrhythmia and Electrophysiology
- Circ Heart Fail: Circulation: Heart Failure
- Circ Interv: Circulation: Cardiovascular Interventions
- Circ Cardiovasc Imaging: Circulation: Cardiovascular Imaging
- Circulation: Cardiovasc Qual Outcomes: Circulation: Cardiovascular Quality and Outcomes
- Clin Cardiol: Clinical Cardiology
- Clin Med Res: Clinical Medicine and Research
- Eur Hear J: European Heart Journal
- Eur Hear J Quality Care Clinical Outcomes: European Heart Journal: Quality of Care & Clinical Outcomes
- Heart Rhythm: Heart Rhythm
- JACC: Journal of the American College of Cardiology
- JACC Cardiovasc Interv: Journal of the American College of Cardiology: Cardiovascular Interventions
- JACC Imaging: Journal of the American College of Cardiology: Cardiovascular Imaging
- JAHA: Journal of the American Heart Association
- JAMA: Journal of the American Medical Association
- JAMA Cardiol: Journal of the American Medical Association: Cardiology
- JAMA Int Med: Journal of the American Medical Association: Internal Medicine
- J Cardiovasc Manag: The Journal of Cardiovascular Management (Pub ended 2005)
- J Cardiovasc Electrophysiol: Journal of Cardiovascular Electrophysiology
- J Invas Cardiol: Journal of Invasive Cardiology
- Journal Biomed Inform: Journal of Biomedical Informatics
- J Cardiovasc. Manag: Journal of Cardiovascular Management
- NEJM: New England Journal of Medicine
- Pharmacoepidemiol Drug Saf: Pharmacoepidemiology and Drug Safety

CathPCI Registry®

PUBLISHED

1. **1.** Rathore SS, Curtis JP, Nallamothu BK, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. Br Med J. 2009;338.
2. **2.** Chakrabarti A, Krumholz HM, Wang TY, et al. Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. Am J Cardiology. 2008;51(25):2442-3.
3. **4.** Anderson HV, Shaw RE, Brindis RG, et al. Risk-Adjusted Mortality Analysis of Percutaneous Coronary Interventions by American College of Cardiology/American Heart Association Guidelines Recommendations. Am J Cardiology. 2007; 99:189–196.
4. **5.** Cardarelli F, Bellasi A, Ou FS, et al. Combined Impact of Age and Estimated Glomerular Filtration Rate on In-Hospital Mortality After Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am J Cardiology. 2009;103(6):766-771.
5. **6.** Kao J, Vicuna R, Rumsfeld J, et al. Effect of Insurance Status on Use of Drug-Eluting Stents versus Bare Metal Stents in Patients Undergoing Elective Percutaneous Coronary Intervention. Am Heart J. 2008;156(6):1133-1140.
6. **7.** Curtis JP, Rathore SS, Wang Y, et al. Use and Effectiveness of Intra-Aortic Balloon Pumps Among Patients Undergoing High Risk Percutaneous Coronary Intervention: Insights from the CathPCI Registry. Circ Cardiovasc Qual Outcomes. 2012;5(1):21-30.
7. **8.** Dodson JA, Wang Y, Chaudhry SI, et al. Bleeding-Avoidance Strategies and Outcomes in Patients >80 Years of Age With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the NCDR® CathPCI Registry®). Am J Cardiology. 2012;110(1):1-6.
8. **9.** Anderson HV, Shaw RE, Brindis RG, et al. Relationship between procedure indications and outcomes of percutaneous coronary interventions by the American College of Cardiology/American Heart Association Task Force Guidelines. Circulation. 2005;112(18):2786–2791.
9. **10.** Dehmer GJ, Kutcher MA, Dey SK, et al. Frequency of Percutaneous Coronary Interventions at Facilities without On-Site Cardiac Surgical Backup—A Report from the American College of Cardiology–National Cardiovascular Data Registry (ACC-NCDR®). Am J Cardiology. 2007; 99:329–332.
10. **11.** Huang HW, Brent BN, Shaw RE. Trends in Percutaneous Versus Surgical Revascularization of Unprotected Left Main Coronary Stenosis in the Drug-Eluting Stent Era—A Report from the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Catheter Cardiovasc Interventions. 2006; 68:867–872.
11. **12.** Tavris DR, Gallauresi B, Brindis RG. "Hemostatic Devices" Chapter in: Medical Device Epidemiology and Surveillance. John Wiley & Sons, Ltd. England 2007, pages 379-394.
12. **13.** Krone RJ, Shaw RE, Klein LW, et al. Ad Hoc Percutaneous Coronary Intervention (PCI) in Patients with Stable Coronary Artery Disease—A Study of Prevalence, Safety, and Variation in Use from the American College of Cardiology—National Cardiovascular Data Registry. Catheter Cardiovasc Interv. 2006;68(5):696–703.
13. **14.** Brener SJ, Milford-Beland S, Roe MT, et al. Culprit-only or multi-vessel revascularization in patients with acute coronary syndromes; An ACC-NCDR report. Am Heart J. 2008; 155:140-6.

14. **15.** Lin GA, Redberg RF, Anderson HV, et al. Impact of Changes in Clinical Practice Guidelines on Assessment of Quality of Care. Medical Care. 2010;48(8):733-738.
15. **16.** Shaw LJ, Shaw RE, Merz CN, et al. Impact of Ethnicity and Gender Differences on Angiographic Coronary Artery Disease Prevalence and In-Hospital Mortality in the American College of Cardiology National Cardiovascular Data Registry. Circulation. 2008;117;1787-1801.
16. **17.** Krone RJ, Shaw RE, Klein LW, et al. Evaluation of the American College of Cardiology/ American Heart Association and the Society for Coronary Angiography and Interventions Lesion Classification System in the Current 'Stent Era' of Coronary Interventions. Am J Cardiol. 2003; 92:389–394.
17. **18.** Klein LW, Shaw RE, Krone RJ, et al. Mortality after Emergent PCI in Cardiogenic Shock Secondary to Acute Myocardial Infarction and Usefulness of a Mortality Prediction Model. Am J Cardiol. 2005;96(1):35–41.
18. **19.** Brindis RG, Dehmer GJ, et al. Continuous quality improvement in the cardiac catheterization laboratory - Are the benefits worth the cost and effort? Circulation. 2006;113(6):767–770.
19. **20.** Shaw RE, Anderson HV, Brindis RG, et al. Development of a Risk Adjustment Mortality Model Using the American College of Cardiology—National Cardiovascular Data Registry Experience: 1998-2000. JACC. 2002;39(7):1104–1112.
20. **21.** Anderson HV, Shaw RE, Brindis RG, et al. A Contemporary Overview of Percutaneous Coronary Interventions: The American College of Cardiology—National Cardiovascular Data Registry. JACC. 2002;39(7):1096–1103.
21. **22.** Klein LW, Block P, Brindis RG, et al. Percutaneous Coronary Interventions in Octogenarians in the American College of Cardiology—National Cardiovascular Data Registry: Development of a Nomogram Predicative of In-Hospital Mortality. JACC. 2002;40(3):394–402.
22. **23.** Brindis RG, Fitzgerald S, Anderson HV, et al. The American College of Cardiology- National Cardiovascular Data Registry™ (ACC-NCDR™): Building a National Clinical Data Repository. JACC. 2001;37(8):2240–2245.
23. **24.** Brindis RG, Fitzgerald S, Anderson HV, et al. The ACC-NCDR: Building a National Clinical Data Repository. JACC. 2001;37(8):2240–2245.
24. **25.** Wang TY, Peterson ED, Dai D, et al. Patterns of Cardiac Marker Surveillance After Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: A Report from the National Cardiovascular Data Registry (NCDR). JACC. 2008;51(21):2068-2074.
25. **26.** Rao SV, Ou FS, Wang TY, et al. Trends in the Prevalence and Outcomes of Radial and Femoral Approaches to Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2008; 1:379-386.
26. **27.** Cavender MA, Milford-Beland S, Roe MT, et al. Prevalence, predictors, and in-hospital outcome of non-infarct artery Intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results from the National Cardiovascular Data Registry (NCDR). Am J Cardiol. 2009; 104:507–513.
27. **28.** Mehta SK, Frutkin AD, Milford-Beland S, et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol. 2007;100(7):1114–1118.
28. **29.** Kutcher MA, Klein LW, Ou FS, et al. Percutaneous Coronary Interventions in Facilities without Cardiac Surgery On-Site: A Report from the National Cardiovascular Data Registry (NCDR). JACC. 2009; 59:16-24.
29. **30.** Rao SV, Shaw RE, Brindis RG, et al. On- versus Off-Label Use of Drug-Eluting Coronary Stents in Clinical Practice: Report from the ACC-NCDR. Am J Cardiol. 2006;97(10):1478–1481.
30. **31.** Rao SV, Shaw RE, Brindis RG, et al. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. Am Heart J. 2006;152(2):321–6.

31. **32.** Dehmer GJ, Hirshfeld JW, Oetgen WJ, et al. CathKIT: Improving Quality in the Cardiac Catheterization Laboratory. JACC. 2004; 43:893–9.
32. **33.** Dehmer GJ, Elma M, Hewitt K, et al. Bringing Measurement and Management Science to the Cath Laboratory: The ACC-NCDR and the Cardiac Catheterization Laboratory Continuous Quality Improvement Toolkit. J Cardiovasc Manag. 2004;15(6):20–6.
33. **34.** Tavris DR, Gallauresi BA, Lin B, et al. Risk of Local Adverse Events Following Cardiac Catheterization by Hemostasis Device Use and Gender. J Invas Cardiol. 2004;16(9):459-64.
34. **35.** Tavris DR, Dey S, Albrecht-Gallauresi B, et al. Risk of Local Adverse Events following Cardiac Catheterization by Hemostasis Device Use — Phase II. J Invas Cardiol. 2005;17:644–650.
35. **36.** Tavris DR, Gallauresi BA, Dey S, et al. Risk of local adverse events by gender following cardiac catheterization. Pharmacoepidemiology and Drug Safety. 2007; 16:125–131.
36. **37.** Shaw RE, Anderson HV, Brindis RG, et al. Updated Risk-Adjustment Mortality Model Using the Complete 1.1 Dataset from the ACC-NCDR J Invas Cardiol. 2003;15(10):578–580.
37. **38.** Weintraub WS, et al. Development of the American College of Cardiology National Cardiovascular Data Registry. J Invas Cardiol. 1998;10(8):489-491.
38. **39.** Grantham JA, Marso SP, Spertus J, et al. Chronic total occlusion angioplasty in the United States. JACC Cardiovasc Interv. 2009;2(6):479-486.
39. **40.** Frutkin AD, Lindsey JB, Mehta SK, et al. Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients with Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization: Analysis from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2009;2(7):614–21.
40. **41.** Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm from the National Cardiovascular Data Registry. Circ Interv. 2009; 2:222-229.
41. **42.** Akhter N, Milford-Beland S, Roe MT, et al. Gender Differences Among Patients with Acute Coronary Syndromes (ACS) Undergoing Percutaneous Coronary Intervention (PCI) in the American College of Cardiology-National Cardiovascular Data Registry. Am Heart J. 2009; 157:141-8.
42. **43.** Ting HH, Roe MT, Gersh BJ, et al. Factors Associated with Off-label Use of Drug Eluting Stents in Patients with ST-elevation Myocardial Infarction. Am J Cardiol. 2008; 101:286-292.
43. **44.** Dixon WC 4th, Wang TY, Dai D, et al. Anatomic Distribution of the Culprit Lesion in Patients with Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. JACC. 2008;15(16):1347-1351.
44. **45.** Singh M, Peterson ED, Milford-Beland S, et al. Validation of the Mayo clinic risk score for in-hospital mortality after percutaneous coronary interventions using the national cardiovascular data registry. Circ Cardiovasc Interv. 2008;1(1):36-44.
45. **46.** Aggarwal A, Dai D, Rumsfeld JS, et al. Impact of Home Warfarin Use on the Treatment and Outcomes of Patients Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2008; 101:1413–1417.
46. **47.** Burjonroppa SC, Varosy PD, Rao SV, et al. Survival of Patients Undergoing Rescue Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2011;4(1):42-50.
47. **48.** Aggarwal A, Dai D, Rumsfeld JS, et al. Incidence and Predictors of Stroke Associated with Percutaneous Coronary Intervention. Am J Cardiol. 2009; 104:349–353.
48. **49.** Wang TY, Peterson ED, Dai D, et al. Patterns of Cardiac Marker Surveillance after Elective Percutaneous Coronary Intervention: Implications for the Use of Peri-procedural Myocardial Infarction as a Quality Metric. JACC. 2008; 51:2068-2074.
49. **50.** Kim MS, Wang TY, Dai D, et al. Association of previous coronary artery bypass graft surgery with door-to-balloon time and in-hospital outcomes: a report from the National Cardiovascular Data Registry (NCDR). JACC. 2008;52(20):1665-70.

50. **51.** Nallamothu BK, Wang Y, Bradley EH, et al. Comparing hospital performance in door-to-balloon time between the Hospital Quality Alliance and the National Cardiovascular Data Registry. JACC. 2007;50(15):1517-9.
51. **52.** Singh M, Peterson ED, Roe MT, et al. Trends in the Association between Age and In-Hospital Mortality Following PCI: National Cardiovascular Data Registry Experience. Circ Interv. 2018;11(1).
52. **53.** Borden WB, Redberg RF, Mushlin AI, et al. Patterns and Intensity of Medical Therapy in Patients Undergoing Percutaneous Coronary Intervention. JAMA. 2011;305(8):1882-1889.
53. **54.** Borden WB, Spertus JA, Mushlin AI, et al. Antianginal Therapy Before Percutaneous Coronary Intervention. Circ Interv. 2013;6(4).
54. **55.** Krone RJ, Rao SV, Dai D, et al. Acceptance, Panic, and Partial Recovery: The Pattern of Usage of Drug-Eluting Stents After Introduction in the U.S. (A Report from the American College of Cardiology/National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2010;3(9):903-910.
55. **56.** Mehta RH, Ou FS, Peterson ED, et al. Clinical Significance of Post-Procedural Thrombolysis in Myocardial Infarction Flow in Patients with Cardiogenic Shock Undergoing Primary Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2009;2(1):56-64.
56. **57.** Lichtman JH, Wang Y, Jones SB, et al. Age and sex differences in in-hospital complication rates and mortality after percutaneous coronary intervention procedures: Evidence from the NCDR®. Am Heart J. 2014;167(3):376-383.
57. **58.** Wang TY, Peterson ED, Ou FS, et al. Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: A report from the National Cardiovascular Data Registry. Am Heart J. 2011;161(1):76-83.
58. **59.** Peterson ED, Dai D, DeLong ER, et al. Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results from 588,398 Procedures in the National Cardiovascular Data Registry. JACC. 2010;55(18):1923-1932.
59. **60.** Brilakis ES, Wang TY, Rao SV, et al. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. JACC Cardiovasc Interv. 2010;3(10):1068-73.
60. **61.** Brilakis ES, Rao SV, Banerjee S, et al. Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2011;4(8):844-50.
61. **62.** Deyell MW, Buller CE, Miller LH, et al. Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Archives of Internal Medicine. 2011;171(18):1636-43.
62. **63.** Cram P, House JA, Messenger JC, et al. Indications for percutaneous coronary interventions performed in US hospitals: a report from the NCDR®. Am Heart J. 2012;163(2):214-21.
63. **64.** Cram P, House JA, Messenger JC, et al. Percutaneous coronary intervention outcomes in US hospitals with varying structural characteristics: analysis of the NCDR®. Am Heart J. 2012;163(2):222-9.
64. **65.** Wang TY, McCoy LA, Messenger JC, et al. Cardiac biomarker measurement after elective percutaneous coronary interventions in older patients: Insights from the National Cardiovascular Data Registry. Am Heart J. 2013;166(5):927-34.
65. **66.** Harrison RW, Aggarwal A, Ou FS, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2013;111(2):178-84.

66. **67.** Owan TE, Roe MT, Messenger JC, et al. Contemporary use of adjunctive thrombectomy during primary percutaneous coronary intervention for ST-elevation myocardial infarction in the United States. Catheter Cardiovasc Interv. 2012;80(7):1173-80.
67. **68.** Resnic FS, Wang TY, Arora N, et al. Quantifying the learning curve in the use of a novel vascular closure device: an analysis of the NCDR (National Cardiovascular Data Registry) CathPCI registry. JACC Cardiovasc Interv. 2012;5(1):82-9.
68. **69.** Maddox TM, Ho PM, Roe M, et al. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. Circ Cardiovasc Qual Outcomes. 2010;3(6):632-41.
69. **70.** Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. NEJM. 2010;362(10):886-95.
70. **71.** Douglas PS, Patel MR, Bailey SR, et al. Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. JACC. 2011;58(8):801-9.
71. **74.** Tsai TT, Messenger JC, Brennan JM, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. JACC. 2011;58(18):1859-69.
72. **75.** Brennan JM, Dai D, Patel MR, et al. Characteristics and long-term outcomes of percutaneous revascularization of unprotected left main coronary artery stenosis in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. JACC. 2012;59(7):648-54.
73. **76.** Hillegass WB, Patel MR, Klein LW, et al. Long-term outcomes of older diabetic patients after percutaneous coronary stenting in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. JACC. 2012;60(22):2280-9.
74. **77.** Kumar RS, Douglas PS, Peterson ED, et al. Effect of Race and Ethnicity on Outcomes with Drug-Eluting and Bare Metal Stents Results in 423,965 Patients in the Linked National Cardiovascular Data Registry and Centers for Medicare & Medicaid Services Payer Databases. Circulation. 2013;127(13):1395-403.
75. **78.** Kutcher MA, Brennan JM, Rao SV, et al. Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: A report from the national cardiovascular data registry. Catheter Cardiovasc Interv. 2014;83(2):171-181.
76. **79.** Wang TY, Masoudi FA, Messenger JC, et al. Percutaneous coronary intervention and drug-eluting stent use among patients ≥85 years of age in the United States. JACC. 2012;59(2):105-12.
77. **80.** Patel MR, Marso SP, Dai D, et al. Comparative effectiveness of drug-eluting versus bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: results from the National Cardiovascular Data Registry, 2005-2008. JACC Cardiovasc Interv. 2012;(10):1054-1061.
78. **81.** Anderson ML, Peterson ED, Brennan JM, et al. Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. Circulation. 2012;126(18):2190-9.
79. **82.** Brennan JM, Peterson ED, Messenger JC, et al. Linking the National Cardiovascular Data Registry CathPCI Registry with Medicare claims data: validation of a longitudinal cohort of elderly patients undergoing cardiac catheterization. Circ Cardiovasc Qual Outcomes. 2012;5(1):134-40.
80. **84.** Mudrick DW, Shah BR, McCoy LA, et al. Patterns of stress testing and diagnostic catheterization after coronary stenting in 250,350 Medicare beneficiaries. Circ Cardiovasc Imaging. 2013;6(1):11-9.
81. **85.** Shah BR, McCoy LA, Federspiel JJ, et al. Use of Stress Testing and Diagnostic Catheterization After Coronary Stenting Association of Site-Level Patterns with Patient

Characteristics and Outcomes in 247,052 Medicare Beneficiaries. JACC. 2013;62(5):439-446. doi: 10.1016/j.jacc.2013.02.093.

82. **86.** Mudrick D, Kaltenbach LA, Shah B, et al. Downstream testing and subsequent procedures after coronary computed tomographic angiography following coronary stenting in patients ≥65 years of age. Am J Cardiol. 2012;110(6):776-83.
83. **88.** Federspiel JJ, Mudrick DW, Shah BR, et al. Patterns and predictors of stress testing modality after percutaneous coronary stenting: data from the NCDR®. JACC Imaging. 2012;5(10):969-80.
84. **90.** Tsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA. 2009;302(22):2458-64.
85. **91.** Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010;303(21):2156-64.
86. **92.** Douglas PS, Brindis RG, et al. President's page: a question of quality: why national benchmarking? JACC. 2006;47(5):1076-8.
87. **93.** Habash-Bseiso DE, Rokey R, Berger CJ, et al. Accuracy of noninvasive ejection fraction measurement in a large community-based clinic. Clin Med Res. 2005;3(2):75-82.
88. **94.** Matheny ME, Ohno-Machado L, Resnic FS, et al. Discrimination and calibration of mortality risk prediction models in interventional cardiology. Journal Biomed Inform. 2005;38(5):367-75.
89. **95.** Chin CT, Weintraub WS, Dai D, et al. Trends and predictors of length of stay after primary percutaneous coronary intervention: a report from the CathPCI registry. Am Heart J. 2011;162(6):1052-61.
90. **96.** Chin CT, Messenger JC, Dai D, et al. Comparison of percutaneous coronary intervention for previously treated versus de novo culprit lesions in acute myocardial infarction patients: insights from the National Cardiovascular Data Registry. Am Heart J. 2014;167(3):393-400.
91. **97.** Gupta N, Kontos MC, Gupta A, et al. Characteristics and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Following Cardiac Arrest (from the NCDR). 2014;113(7):1087-1092.
92. **98.** Stribling WK, Kontos MC, Abbate A, et al. Left circumflex occlusion in acute myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2011;108(7):959-63.
93. **99.** Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. JAMA. 2011;306(1):53-61.
94. **100.** Parikh NI, Honeycutt EF, Roe MT, et al. Left and codominant coronary artery circulations are associated with higher in-hospital mortality among patients undergoing percutaneous coronary intervention for acute coronary syndromes: report From the National Cardiovascular Database Cath Percutaneous Coronary Intervention (CathPCI) Registry. Circ Cardiovasc Qual Outcomes. 2012;5(6):775-82.
95. **101.** Curtis JP, Geary LL, Wang Y, et al. Development of 2 registry-based risk models suitable for characterizing hospital performance on 30-day all-cause mortality rates among patients undergoing percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes. 2012;5(5):628-37.
96. **102.** Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv. 2012;5(2):131-40.
97. **103:** Brennan JM, Sketch MH, Dai D, et al. Safety and Clinical Effectiveness of Drug-Eluting Stents for Saphenous Vein Graft Stenting in Older Individuals: Results from the Medicare-linked National Cardiovascular Data Registry® CathPCI Registry® (2005-2009). 2016;87(1):43-49.

98. **104.** Amin AP, Marso SP, Rao SV, et al. Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. Circ Cardiovasc Qual Outcomes. 2010;3(4):358-65.
99. **106.** Valle JA, McCoy LA, Maddox TM, et al. Longitudinal Risk of Adverse Events in Patients with Acute Kidney Injury After Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry. Circ Interv. 2017;10(4).
100. **107.** Wang TY, McCoy LA, Bhatt DL, et al. Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction. Am Heart J. 2016; 172:9-18.
101. **109A.** Fazel R, Curtis J, Wang Y, et al. Determinants of fluoroscopy time for invasive coronary angiography and percutaneous coronary intervention: Insights from the NCDR®. Catheter Cardiovasc Interv. 2013;82(7):1091-1105.
102. **109B.** Rao SV, Dai D, Subherwal S, et al. Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv. 2012;5(9):958-65.
103. **110.** Subherwal S, Peterson ED, Dai D, et al. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. JACC. 2012;59(21):1861-9.
104. **111.** Kohsaka S, Miyata H, Ueda I, et al. An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database–Keio interhospital Cardiovascular Studies (JCD-KiCS)**.** Am Heart J. 2015;170(6):1077-1085.
105. **112.** Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. JAMA. 2011;306(13):1461-7.
106. **114.** Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA. 2013;309(10):1022-9.
107. **115.** Dattilo PB, Prasad A, Honeycutt E, et al. Contemporary patterns of fractional flow reserve and intravascular ultrasound use among patients undergoing percutaneous coronary intervention in the United States: insights from the National Cardiovascular Data Registry. JACC. 2012;60(22):2337-9.
108. **116.** Baklanov DV, Kim S, Marso SP, et al. Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry. Circ Cardiovasc Interv. 2013;6(4):347-53.
109. **117.** Daugherty SL, Thompson LE, Kim S, et al. Patterns of Use and Comparative Effectiveness of Bleeding Avoidance Strategies in Men and Women Following Percutaneous Coronary Interventions: An Observational Study from the National Cardiovascular Data Registry®. JACC. 2013;61(20):2070-2078.
110. **118.** Amin AP, Spertus JA, Cohen DJ, et al. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Archives of Internal Medicine. 2012;172(15):1145-52.
111. **119.** Menees DS, Peterson ED, Wang Y, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. NEJM. 2013;369(10):901-9.
112. **121.** Abdallah MS, Spertus JA, Nallamothu BK, et al. Symptoms and Angiographic Findings of Patients Undergoing Elective Coronary Angiography Without Prior Stress Testing. Am J Cardiol. 2014;114(3):348-354.
113. **122.** Yeh RW, Czarny MJ, Normand ST, et al. Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial: Comparing Hospitals and Patients in the Dual Antiplatelet

Therapy Study Versus the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015;8(1):96-102.

114. **123.** Swaminathan RV, Wang TY, Kaltenbach LA, et al. Non-System Reasons for Delay in Door- To-Balloon Time and Associated In-Hospital Mortality: A Report from the NCDR®. JACC. 2013;61(16):1688-1695.
115. **124.** Kontos MC, Wang Y, Chaudhry SI, et al. Lower Hospital Volume Is Associated with Higher In-Hospital Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment –Elevation Myocardial Infarction: A Report From the NCDR. Circ Cardiovasc Qual Outcomes. 2013;6(6):659-67.
116. **125.** Chan PS, Rao SV, Bhatt DL, et al. Patient and Hospital Characteristics Associated with Inappropriate Percutaneous Coronary Interventions. JACC. 2013;62(24):2274-81.
117. **126.** Bradley SM, Chan PS, Spertus JA, et al. Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR. Circ Cardiovasc Qual Outcomes. 2012;5(3):290-7.
118. **127.** Tavris DR, Wang Y, Jacobs S, et al. Bleeding and vascular complications at the femoral access site following percutaneous coronary intervention (PCI): an evaluation of hemostasis strategies. Journal of Invasive Cardiology. 2012;24(7):328-34.
119. **128.** Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. Circulation. 2012;125(12):1501-10.
120. **129A.** Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. NEJM. 2012;366(16):1467-76.
121. **129B.** Zhang Z, Kolm P, Grau-Sepulveda MV, et al. Cost-Effectiveness of Revascularization Strategies: The ASCERT Study. JACC. 2015; 65:1–11.
122. **129C.** Chakrabarti AK, Grau-Sepulveda MV, O'Brien S, et al. Angiographic validation of the American College of Cardiology Foundation-the Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies study. Circ Cardiovasc Interv. 2014;7(1):11-8.
123. **131.** Rao S, McCoy L, Spertus J, et al. An Updated Bleeding Model to Predict the Risk of Post-Procedure Bleeding Among Patients Undergoing Percutaneous Coronary Intervention: A Report Using an Expanded Bleeding Definition From the National Cardiovascular Data Registry CathPCI Registry. JACC Cardiovasc Interv. 2013;6(6):897-904**.**
124. **132.** Hess CN, Rao SV, McCoy LA, et al. Identification of Hospital Outliers in Bleeding Complications After Percutaneous Coronary Intervention. Circ Cardiovasc Qual Outcomes. 2015;11(1).
125. **133.** Dehmer GJ, Weaver D, Roe MT, et al. A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011. JACC. 2012;60(20):2017-31.
126. **134.** Spertus JA, Decker C, Gialde E, et al. Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks. Br Med J. 2015;350.
127. **135.** Sherwood MW, Wang Y, Curtis JP, et al. Patterns and Outcomes of Red Blood Cell Transfusion in Patients Undergoing Percutaneous Coronary Intervention. JAMA. 2014;311(8):836-843. doi:10.1001/jama.2014.980.
128. **136.** Payvar S, Kim S, Rao SV, et al. In-Hospital Outcomes of Percutaneous Coronary Interventions in Extremely Obese and Normal-Weight Patients: Findings From the NCDR (National Cardiovascular Data Registry). JACC. 2013;62(8):692–6.

129. **137.** Cavender MA, Joynt KE, Parzynski CS, et al. State Mandated Public Reporting and Outcomes of Percutaneous Coronary Intervention in the United States. Am J Cardiol. 2015;115:1494-1501.
130. **138.** Vora AN, Peterson ED, McCoy LA, et al. The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry CathPCI Registry. JACC Cardiovasc Interv. 2016;9(8):771-779.
131. **140A.** Hess CN, Rao SV, Kong DF, et al. Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). Am Heart J. 2013;166(3):421-428.
132. **140B:** Hess CN, Krucoff MW, Rao SV, et al. Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life sub study. Am Heart J. 2015;170(2):371-379.
133. **141.** Rao SV, Hess CN, Barham B, et al. A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention: The SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) Trial. JACC Cardiovasc Interv. 2014;7(8):857-867.
134. **142.** Hawkins BM, McCoy LA, Neely M, et al. Impact of Academic Year Timing on PCI Outcomes at Training Institutions. JACC. 2014;63(10):1025-30.
135. **143.** Sherwood MW, Brennan MJ, Ho KK, et al. The Impact of Extreme-Risk Cases on Hospitals' Risk-Adjusted Percutaneous Coronary Intervention Mortality Ratings. JACC Cardiovasc Interv. 2015;8(1):10-16.
136. **144.** Rymer JA, Harrison RW, Dai D, et al. Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥ 65 Years (from the CathPCI Registry). Am J Cardiol. 2016;118(7):959-966.
137. **145.** Brennan JM, Curtis JP, Dai D, et al. Enhanced Mortality Risk Prediction With a Focus on High-Risk Percutaneous Coronary Intervention Results From 1,208,137 Procedures in the NCDR. JACC Cardiovasc Interv. 2013;6(8):790-799.
138. **146.** Feldman DN, Swaminathan RV, Kaltenbach LA, et al. Adoption of Radial Access and Comparison of Outcomes to Femoral Access in Percutaneous Coronary Intervention an Updated Report from the National Cardiovascular Data Registry (2007–2012). Circulation. 2013;127:2295-2306.
139. **147**. Baklanov DV, Kaltenbach LA, Marso SP, et al. The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). JACC. 2013;61(4):420-6.
140. **148A.** Tsai TT, Patel UD, Chang TI, et al. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights From the NCDR Cath-PCI Registry. JACC Cardiovasc Interv. 2014;7(1):1–9.
141. **148B.** Tsai TT, Patel UD, Chang TI, et al. Validated Contemporary Risk Model of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights from the National Cardiovascular Data Registry Cath-PCI Registry. JAHA. 2014;3(6).
142. **149.** Chin CT, Wang, TY, Anstrom KJ, et al. Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. Am Heart J. 2011;162(5):844-851.

143. **151.** Fiorilli PN, Minges KE, Curtis JP, et al. Association of Physician Certification in Interventional Cardiology with In-Hospital Outcomes of Percutaneous Coronary Intervention. Circulation. 2015;132(19):1816-1824.
144. **152.** Hess CN, Rao SV, Dai D, et al. Predicting target vessel revascularization in older patients undergoing percutaneous coronary intervention in the drug-eluting stent era. Am Heart J. 2014;167(4):576-584.
145. **153.** Bradley SM, Spertus JA, Kennedy, KF et al. Patient Selection for Diagnostic Coronary Angiography and Hospital-Level Percutaneous Coronary Intervention Appropriateness: Insights from the National Cardiovascular Data Registry. JAMA Int Med. 2014;174(10):1630-1639.
146. **154.** Patel MR, Dai D, Hernandez AF, et al. Prevalence and predictors of non-obstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. Am Heart J. 2014;167(6):846-852.
147. **156.** Amin AP, Patterson M, House JA, et al. Costs Associated with Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States. JACC Cardiovasc Interv. 2017;4:342-351.
148. **157.** Safley DM, Venkitachalam L, Kennedy KF, et al. Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2015;8(12):1574-1582.
149. **158.** Hess CN, Peterson ED, Neely ML, et al. The Learning Curve for Transradial Percutaneous Coronary Intervention among Operators in the United States: A Study from the National Cardiovascular Data Registry. Circulation. 2014;129(22):2277-86.
150. **159.** Aragam KG, Dai D, Gurm H, et al. Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States. JACC. 2015;65:2079–88.
151. **160.** Aronow HD, Gurm HS, Blankenship JC, et al. Middle-of-the-Night Percutaneous Coronary Intervention and its Association with Percutaneous Coronary Intervention Outcomes Performed the Following Day: An Analysis from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2015;8:49–56.
152. **162.** Moussa I, Hermann A, Messenger JC, et al. The NCDR CathPCI Registry: a US national perspective on care and outcomes for percutaneous coronary intervention. Heart. 2013;99(5):297-303.
153. **165.** Thomas MP, Parzynski CS, Curtis JP, et al. Percutaneous Coronary Intervention Utilization and Appropriateness across the United States. PLOS ONE. 2015;10(9).
154. **166.** Boyden TF, Joynt KE, McCoy L, et al. Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan. Am Heart J. 2015;170;1227-1233.
155. **168.** Minges KE, Herrin J, Fiorilli PN, et al. Development and Validation of a Simple Risk Score to Predict 30-day Readmission After Percutaneous Coronary Intervention in a Cohort of Medicare Patients. Catheter Cardiovasc Interv. 2017;89:955-963.
156. **170.** Nallamothu BK, Spertus JA, Lansky AJ, et al. Comparison of Clinical Interpretation with Visual Assessment and Quantitative Coronary Angiography in Patients Undergoing Percutaneous Coronary Intervention in Contemporary Practice: The Assessing Angiography (A2) Project. Circulation. 2013;127(17):1793-1800.
157. **171.** Brilakis ES, Banerjee S, Karmpaliotis D, et al. Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention a Report from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2015;8(2).

158. **172:** Swaminathan RV, Rao SV, McCoy LA, et al. Hospital Length of Stay and Clinical Outcomes in Older STEMI Patients After Primary PCI A Report from the National Cardiovascular Data Registry. JACC. 2015;65(12):1161–71.
159. **173.** Bradley SM, Rao SV, Curtis JP, et al. Change in Hospital-Level Use of Transradial Percutaneous Coronary Intervention and Periprocedural Outcomes: Insights from the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2014;7(4).
160. **174.** Motivala AA, Parikh V, Roe M, et al. Predictors, Trends, and Outcomes (Among Older Patients >65 Years of Age) Associated with Beta-Blocker Use in Patients with Stable Angina Undergoing Elective Percutaneous Coronary Intervention Insights from the NCDR Registry. JACC Cardiovasc Interv. 2016;9(16):1639-1648.
161. **175.** Wang TY, Grines C, Ortega R, et al. Women in Interventional Cardiology: Update in Percutaneous Coronary Intervention Practice Patterns and Outcomes of Female Operators from the National Cardiovascular Data Registry. Catheter Cardiovasc Interv. 2015;9(8).
162. **176.** Baber U, Giustino G, Wang T, et al. Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. Coronary Artery Disease. 2016;27(6):442–448.
163. **178.** Wimmer NJ, Secemsky EA, Mauri L, et al. Effectiveness of Arterial Closure Devices for Preventing Complications with Percutaneous Coronary Intervention: An Instrumental Variable Analysis. Circ Interv. 2016;9(4).
164. **179.** Kadakia MB, Desai NR, Alexander KP, et al. Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted with Myocardial Infarction. JACC Cardiovasc Interv. 2015;3(11):1166-1177.
165. **180.** Dasari TW, Saucedo JF, Krim S, et al. Clinical Characteristics and in-hospital Outcomes of Heart Transplant Recipients with Allograft Vasculopathy Undergoing Percutaneous Coronary Intervention: Insights from The National Cardiovascular Data Registry. Am Heart J. 2015;170(6):1086-1091.
166. **193.** Wayangankar SA, Bangalore S, McCoy LA, et al. Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report from the CathPCI Registry. JACC Cardiovasc Interv. 2016;9(4):341-351.
167. **194.** Sandhu A, McCoy LA, Negi SI, et al. Utilization of Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention: Insights From the NCDR. Circulation. 2015;137(5).
168. **196.** Doll JA, Dai D, Roe MT, et al. Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2017;10(7):672-682.
169. **212.** Vora AN, Dai D, Gurm H, et al. Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention a Report from the National Cardiovascular Data Registry's CathPCI Registry. Circ Interv. 2016;9(3).
170. **216.** Chui PW, Parzynski CS, Ross JS, et al. Association of Statewide Certificate of Need Regulations with Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association. 2019.
171. **222.** Anderson L, Dai D, Miller AL, et al. Percutaneous Coronary Intervention for Older Adults Who Present with Syncope and Coronary Artery Disease. Insights from the National Cardiovascular Data Registry®. Am Heart J. 2016;176:1-9.
172. **224.** Karrowni W, Vora AN, Dai D, et al. Blood Transfusion and the Risk of Acute Kidney Injury Among Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Circ Interv. 2016;9(9).
173. **230.** Yea, K, Azarbal, F, Zakroysky, P et al. Differential Longitudinal Outcomes Following Percutaneous Coronary Intervention to the Left Internal Mammary Artery and

Other Bypass Grafts of the LAD: Findings From the NCDR. J INVASIVE CARDIOL 2020;32(6):E143-E150.

174. **242.** Resnic FS, Majithia A, Marinac-Dabic D, et al. Registry-Based Prospective, Active Surveillance of Medical-Device Safety. NEJM. 2017;376:526-35.
175. **243.** Chui PW, Parzynski CS, Nallamothu BK, et al. Hospital Performance on PCI Process and Outcomes Measures. JAHA. 2017;6(5).
176. **244A.** Desai NR, Bradley SM, Parzynski CS, et al. Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. JAMA. 2015;314(19):2045-2053.
177. **244B**. Masoudi FA, Curtis JP, Desai NR, et al. PCI Appropriateness in New York. JACC. 2017;69(10):1243-1246.
178. **248A.** Secemsky EA, Kirtane A, Bangalore S. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States; JACC Cardiovasc Interv. 2016;9(23):2376-2386.
179. **248B.** Secemsky EA, Kirtane A, Bangalore S, et al. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non–ST-Segment–Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. Circulation: Cardiovascular Quality and Outcomes. 2017.
180. **253B**: Brennan JM, Al-Hejily W, Dai D, et al. Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention Results in 49 325 Senior Patients in the Medicare-Linked National Cardiovascular Data Registry CathPCI Registry. Circ Cardiovasc Interv. 2015;8(3).
181. **264.** Desai NR, Parzynski CS, Krumholz HM, et al. Patterns of Institutional Review of Percutaneous Coronary Intervention Appropriateness and the Effect on Quality of Care and Clinical Outcomes. JAMA Int Med. 2015;175(12):1988-90.
182. **272.** Schulman-Marcus J, Feldman DN, Rao SV, et al. Characteristics of Patients Undergoing Cardiac Catheterization Before Noncardiac Surgery: A Report from the National Cardiovascular Data Registry CathPCI Registry. JAMA Int Med. 2016;176(5):611-618.
183. **276.** Dreyer RP, Tavella R, Curtis JP, et al. Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population. European Heart Journal. 14 February 2020.
184. **289.** Acharya T, Salisbury AC, Spertus JA, et al. In-Hospital Outcomes of Percutaneous Coronary Intervention in America's Safety Net: Insights from the NCDR Cath-PCI Registry. JACC Cardiovasc Interv. 2017;10(15):1475-1485.
185. **297.** Zheng X, Curtis JP, Hu S, et al. Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results from the China PEACE-Retrospective CathPCI Study. JAMA Intern Med. 2016 Apr.
186. **300.** Jovin IS, Shah RM, Patel DB, et al. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated with Bivalirudin Versus Heparin: A Report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2017;10(11):1102-1111.
187. **303.** Washam JB, Kaltenbach LA, Wojdyla DM, et al. Anticoagulant Use Among Patients with End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis from the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2018;11(2).
188. **305A.** Fanaroff AC, Zakroysky P, Dai D, et al. Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States. JACC. 2017;69(24):2913-2924.
189. **305B.** Nallamothu BK, Normand SLT, Wang Y, et al. Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study. The Lancet. 2015;385(9973):1114-1122.

190. **325.** Alnasser SM, Bagai A, Jolly SS, et al. Transradial approach for coronary angiography and intervention in the elderly: A meta-analysis of 777,841 patients. International Journal of Cardiology. 2017;228:45-51.
191. **327.** Sapontis J, Marso SP, Cohen DJ, et al. The Outcomes, Patient Health Status, and Efficiency IN Chronic Total Occlusion Hybrid Procedures registry: rationale and design. Coronary Artery Disease. 2017;28(2):110-119.
192. **334.** Dehmer GJ, Jennings J, Madden RA, et al. The National Cardiovascular Data Registry Voluntary Public Reporting Program: An Interim Report from the NCDR Public Reporting Advisory Group. JACC. 2016;67(2):205-215.
193. **353.** Castro-Dominguez Y, Wang Y, Minges KE, et al. Predicting In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2021 Jul 20.
194. **357.** Sukul D, Bhatt DL, Seth M, et al. Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Non-Ranked Hospitals in the United States of America. JACC Cardiovasc Interv. Available online November 2017. https://doi.org/10.1016/j.jcin.2017.10.042.
195. **366.** Young MN, Secemsky EA, Kaltenbach LA, et al. Examining the Operator Learning Curve for Percutaneous Coronary Intervention of Chronic Total Occlusions A Report from the National Cardiovascular Data Registry. Circ:CI. 2019 Aug 16.
196. **368.** Valle JA, Kaltenbach LA, Bradley SM, et al. Variation in the Adoption of Transradial Access for ST-Segment Elevation Myocardial Infarction: Insights from the NCDR CathPCI Registry. JACC Cardiovasc Interv. 2017;10(22):2242-2254.
197. **374.** Boehar et al. Role of Mechanical Coronary Atherectomy in the Treatment of Severely Calcified Lesions. Circ Cardiovasc Interv. 2020;13:e008789.
198. **381.** Malik AO, Amin A, Kennedy K, et al. Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention. AHJ. 2021 Apr.
199. **387.** Wu CM, Albert NM, Gluckman TJ, et al. Facilitating the identification of patients hospitalized for acute myocardial infarction and heart failure and the assessment of their readmission risk through the Patient Navigator Program. AHJ. 2020.
200. **391.** Secemsky E, Ferro E, Rao S, et al. Thrombectomy with Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction the National Cardiovascular. JAMA Cardiol. 2019. doi:10.1001
201. **399.** Badri M, Shapiro T, Wang Y, et al. Adoption of the trans radial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from NCDR. Catheter Cardiovasc Interv. 2018;1-7.
202. **405.** Feldman, D, Shroff, A, Bao, H et al. Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry. Catheter Cardiovasc Interv. 2020
203. **419.** Rymer JA, Kaltenbach LA, Kochar A, et al. Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. Circ Cardiovasc Interv. 2019 May.
204. **422.** Bradley SM, Kaltenbach LA, Xiang K, et al. Trends in Use and Outcomes of Same-Day Discharge Following Elective Percutaneous Coronary Intervention. JACC:CI. 2021 Aug 14.
205. **423.** Dhruva SS, Ross JS, Mortazavi BJ, et al. Use of Mechanical Circulatory Support Devices Among Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA Network Open. 2021 Feb 1.
206. **426.** Lowenstern, A, Wu, J, Bradley, S et al. Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry. Am Heart J 2019;215:167-77.
207. **440.** Faridi KF, Rymer JA, Rao SV, et al. Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry. Am Heart J. 2019 Oct.

208. **442.** Moussa ID, Mohananey D, Saucedo J, et al. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. Journal of the American College of Cardiology. 29 September 2020.

209. **446.** Valle J, Tamez H, Abbott J, et al. Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States.JAMA Cardiol.2019; doi:10.1001

210. **477.** Saad M, Tobolski J, Kolte D, et al. Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry). AHJ. OCTOBER 15, 2020.

211. **480.** Amin AP, Miller S, et al. Reversing the "Risk-Treatment Paradox" of Bleeding in Patients Undergoing Percutaneous Coronary Intervention: Risk-Concordant Use of Bleeding Avoidance Strategies Is Associated with Reduced Bleeding and Lower Costs. AHJ. 2018.

212. **493.** Almarzooq ZI, Bhatt DL, et al. Are statins back for patients on hemodialysis? European Journal of Preventive Cardiology. 2021.

213. **494.** Xie J, Kobashigawa J, Kennedy K, et al. Omission of Heart Transplant Recipients from the Appropriate Use Criteria for Revascularization and the Ramifications on Heart Transplant Centers. JAMA Cardiol. 2020

214. **522.** Tamez H, Secemsky EA, Valsdottir LR, et al. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroInterventions. 2021.

215. **523.** Chau K, Kennedy K, Messinger J, et al. Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice an NCDR Registry to Practice Project. JAMA Cardiol. 2019.

216. **545.** Manly DA, Karrowni W, Rymer JA, et al. Characteristics and Outcomes of Patients with History of CABG Undergoing Cardiac Catheterization Via the Radial Versus Femoral Approach. JACC Cardiovasc Interv. 2021 Apr 26.

217. **551.** Nathan, A, Ziang, Q, Wojdyla et al. Performance of Hospitals When Assessing Disease-Based Mortality Compared with Procedural Mortality for Patients with Acute Myocardial Infarction. JAMA Cardiology. 2020

218. **566.** Inohara T, Kohsaka S, Sperus J, et al. Comparative Trends in Percutaneous Coronary Intervention in Japan and the United States, 2013 to 2017.Journal of the American College of Cardiology. 15 September 2020.

219. **568.** Huang, C, Murugiah, K, Mahajan, S et al. Enhancing the prediction of acute kidney injury risk after percutaneous coronary intervention using machine learning techniques: A retrospective cohort study. DOI: 10.1371/journal.pmed.1002703

220. **571**. Dhruva, S, Parzynski, C, Gamble, G et al. Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data.JAHA. 2020

221. **572.** Sintek M, Coverstone E, Bach R, et al. Excimer Laser Coronary Angioplasty in Coronary Lesions: Use and Safety From the NCDR/CATH PCI Registry. Circ:CI. 25 June 2021.

222. **573.** Doll JA, Nelson AJ, Kaltenbach LA, et al. Percutaneous Coronary Intervention Operator Profiles and Associations with In-Hospital Mortality. Circ: CI. 1 December 2021.

223. **590.** Khera, R, Secemsky, E, Wang, Y et al. Coronary Artery Disease Who Presented with Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Intern Med. 2020;180(10):1317-1327. doi:10.1001/jamainternmed.2020.3276

224. **601.** Secemsky EA, Butala N, Raja A, Khera R, Wang Y, Curtis JP, Maddox TM, Virani SS, Armstrong EJ, Shunk KA, Brindis RG, Bhatt D, Yeh RW. Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Among Medicare Beneficiaries with Multivessel Coronary Artery Disease: A National Cardiovascular Data Registry Research to Practice Project. Circ Cardiovasc Interv. 2021 Aug;14(8):e010323. PMID: 34372676.

225. **602.** Omer, M. A., Brilakis, E. S., Kennedy, K. F., Alkhouli, M., Elgendy, I. Y., Chan, P. S., & Spertus, J. A. Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Patients with Non-ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock. JACC Cardiovasc Interv2021
226. **606.** Chatterjee S, Fanaroff AC, Parzynski C, et al. Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice with ISCHEMIA Trial Population. JACC: Cardiovascular Interventions. 8 November 2021.
227. **610.** Lima FV, Manandhar P, Wojdyla D, et al. Percutaneous Coronary Intervention Following Diagnostic Angiography by Noninterventional Versus Interventional Cardiologists: Insights from the CathPCI Registry. Circ Interv. 2022 Jan;15(1).
228. **612.** Nathan A, Manandhar P, Wojdyla D, et al. Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance. JACC. 2021 Nov;78(22)
229. **635.** Malik AO, Spertus JA, Patel MR, et al. Potential Association of the ISCHEMIA Trial with the Appropriate Use Criteria Ratings for Percutaneous Coronary Intervention in Stable Ischemic Heart Disease. JAMA Int Med. 2021 Sept 1.
230. **N/A.** Anstrom KJ, Brennan JM, Eisenstein EL, et al. Examination of the Treatment Selection Process in a Multicenter Observational Study. Circ Cardiovasc Qual Outcomes. 2014;7:764-769.
231. **N/A.** Hess CN, McCoy LA, Duggirala HJ, et al. Sex-Based Differences in Outcomes After Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Report From TRANSLATE-ACS. JAHA. 2014;3(1).

IN PRESS

PUBLISHED

1. **1**. Cudnik MT, Frank Peacock W, Diercks DB, et al. Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. Clin Cardiol. 2009;32(12):668-75.
2. **2**. Roe MT, Chen AY, Cannon CP, et al. Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients suppress Adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. CIRC: Cardiovasc Qual Outcomes. 2009;2(5):414-20.
3. **3**. Lopes RD, Peterson ED, Chen AY, et al. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC Cardiovasc Interv. 2010;3(6):669-77.
4. **4**. Glickman SW, Cairns CB, Chen AY, et al. Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. Am Heart J. 2010;159(6):998-1004.
5. **5**. Melloni C, Roe MT, Chen AY, et al. Use of Early Clopidogrel by Reperfusion Strategy Among Patients Presenting With ST-Segment Elevation Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2011;4(6):603-609.
6. **6**. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121(3):357-65.
7. **7.** Parikh SV, de Lemos JA, Jessen ME, et al. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with The Guidelines). JACC Cardiovasc Interv. 2010;3(4):419-27.
8. **8.** Abtahian F, Olenchock B, Ou FS, et al. Effect of prior stroke on the use of evidence- based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol. 2011;107(10):1441-1446.
9. **9.** Diercks DB, Owen KP, Kontos MC, et al. Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). Am Heart J. 2010;160(1):80-87.
10. **10**. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: Results from the American College of Cardiology's NCDR®. Am Heart J. 2011; 161:864-870.
11. **11**. Kontos MC, de Lemos JA, Ou FS, et al. Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention

Outcomes Network-Get with The Guidelines (NCDR ACTION-GWTG) Registry. Am Heart J. 2010;160(5):819-25.

12. **12**. Scirica BM, Kadakia MB, de Lemos JA, et al. Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: A Report from the ACTION Registry(R)-GWTG™. Clinical Chemistry. 2013;59(8):1205-1214.
13. **13**. Kadakia MB, Desai NR, Alexander KP, et al. Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted with Myocardial Infarction: A Report from the NCDR ACTION Registry GWTG. JACC Cardiovasc Interv. 2010;3;1166-1177.
14. **14**. Desai NB, Peterson ED, Chen AY, et al. Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients – A report from the National Cardiovascular Data Registry. Am Heart J. 2013;166(6):1043-1049.
15. **15**. Wang TY, Magid DJ, Ting HH, et al. The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. Am Heart J. 2014;167(6):833-839.
16. **16.** Kim MS, Wang TY, Ou FS, et al. Association of prior coronary artery bypass graft surgery with quality of care of patients with non-ST-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines. Am Heart J. 2010;160(5):951-7.
17. **17.** Maddox TM, Ho PM, Tsai TT, et al. Clopidogrel Use and Hospital Quality in Medically Managed Patients with Non-ST-Segment-Elevation Myocardial Infarction. CIRC Cardiovasc Qual Outcomes. 2012; 5:523-531.
18. **18.** Leonardi S, Chen AY, Charachalou SM, et al. Limitations of using cardiac catheterization rates to assess the quality of care for patients with non–ST-segment elevation myocardial infarction. Am Heart J. 2012; 164:502-8.
19. **19.** Forman DE, Chen AY, Wiviott SD, et al. Comparison of outcomes in patients aged <75, 75 to 84, and ≥ 85 years with ST-elevation myocardial infarction (from the ACTION Registry-GWTG). Am J Cardiol. 2010;106(10):1382-8.
20. **20.** Wang TY, Nallamothu BK, Krumholz HM, et al. Association of Door-In-Door-Out Time with Reperfusion Delays and Outcomes Among Patients Transferred for Primary Percutaneous Coronary Intervention. JAMA. 2011;305(24);3540-3547.
21. **21.** Subherwal S, Peterson ED, Chen AY, et al. Admission International Normalized Ratio Levels, Early Treatment Strategies, and Major Bleeding Risk Among Non–ST-Segment–Elevation Myocardial Infarction Patients on Home Warfarin Therapy: Insights from the National Cardiovascular Data Registry. CIRC. 2012; 125:1414-1423.
22. **22**. Lopes RD, Li L, Granger CB, et al. Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes. Am J Medicine. 2012; 125:897-905.
23. **23.** Peterson ED, Roe MT, Rumsfeld JS, et al. A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. CIRC Cardiovasc Qual Outcomes. 2009;2(5):491-9.
24. **24**. Peterson ED, Roe MT, Chen AY, et al. The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. Heart. 2010;96(22):1798-802.
25. **25**. Mogabgab O, Wiviott SD, Antman EM, et al. Relation Between Time of Symptom Onset of ST-Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. Clin Cardiol. 2013;36(4):222-227.
26. **26**. Yeo KK, Li S, Amsterdam EA, et al. Comparison of Clinical Characteristics, Treatments and Outcomes of Patients With ST-Elevation Acute Myocardial Infarction with Versus Without New or Presumed New Left Bundle Branch Block (from NCDR®). Am J Cardiol. 2012;109(4)497-501.

27. **27**. Gupta N, Washam JB, Mountantonakis SE, et al. Characteristics, Management, and Outcomes of Cocaine-Positive Patients with Acute Coronary Syndrome (from the National Cardiovascular Data Registry). The American Journal of Cardiology. 2014;113(5):749-756.
28. **28**. Don CW, Roe, MT, Li S, et al. Temporal Trends and practice variations in clopidogrel loading doses in patients with non–ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. Am Heart J. 2011;161(4):689-697.
29. **29**. Fox CS, Muntner P, Chen AY, et al. Health Services and Outcomes Research Short-Term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury A Report from the National Cardiovascular Data Registry. Circulation. 2012; 125:497-504.
30. **30.** Chin CT, Chen AY, Wang TY, et al. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J. 2011;161(1):113-122.
31. **31**. Piña IL, Cohen MG, Rodriguez CJ, et al. Differences in Treatment Patterns and Outcomes Between Hispanics and Infarction: Results from the NCDR ACTION Registry GWTG Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction. JACC. 2012; 59:630-631.
32. **32.** Chin CT, Wang TY, Li S, et al. Comparison of the Prognostic Value of Peak Creatine Kinase-MB and Troponin Levels Among Patients with Acute Myocardial Infarction: A Report from the Acute Coronary Treatment and Intervention Outcomes Network Registry–Get with The Guidelines. Clin Cardiol. 2012;35(7):424-9.
33. **33.** Das SR, Alexander KP, Chen AY, et al. Impact of Body Weight and Extreme Obesity on the Presentation, Treatment, and In-Hospital Outcomes of 50,149 Patients With ST-Segment Elevation Myocardial Infarction: Results from the NCDR (National Cardiovascular Data Registry). JACC. 2011; 58:2642-2650.
34. **34**. Vavalle JP, Lopes RD, Chen AY, et al. Hospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction. Am J Medicine. 2012; 125:1085-1094.
35. **35.** Sherwood MW, Wiviott SW, Peng SA, et al. Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights from the National Cardiovascular Data Registry. JAHA. 2014;3(2).
36. **36.** Hanna EB, Chen AY, Roe MT, et al. Characteristics and In-Hospital Outcomes of Patients with Non–ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2011;4(9):1002-8.
37. **37**. Hanna EB, Chen AY, Roe MT, et al. Characteristics and in-hospital outcomes of patients presenting with non–ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically: Stratification according to renal function. Am Heart J. 2012;164(1): 52-57.
38. **38.** Hanna EB, Alexander KP, Chen AY, et al. Characteristics and In-Hospital Outcomes of Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing an Invasive Strategy According to Hemoglobin Levels. Am J Cardiol. 2013;111(8):1099-1103.
39. **39.** Britton KA, Aggarwal V, Chen AY, et al. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. Am Heart J. 2011;161(4):657-663.
40. **40.** Wiviott SD, Saucedo JF, Antman EM, et al. Use of Emergency Medical Service Transport Among Patients With ST-Segment–Elevation Myocardial Infarction Findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry–Get with the Guidelines. Circulation. 2011; 124:154-163.
41. **41.** Mathews R, Peterson ED, Chen AY, et al. In-Hospital Major Bleeding During ST- Elevation and Non-ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry®-GWTG™. Am J Cardiol. 2011;107(8):1136-43.

42. **42.** Peacock WF, Kontos MC, Amsterdam E, et al. Impact of Society of Cardiovascular Patient Care Accreditation on Quality: An Action Registry®-Get with the Guidelines™ Analysis. Critical Pathways in Cardiology. 2013;12(3):116-120.
43. **43.** McNamara RL, Chung SC, Jernberg T, et al. International Comparisons of the Management of Patients with Non-ST Segment Elevation Acute Myocardial Infarction in the United Kingdom, Sweden, and the United States: The MINAP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR Registries. International Journal of Cardiology. 2014; 175:240-247.
44. **44.** Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. JACC. 2010;56(4):254-63.
45. **45.** Miller AL, Dib C, Li L, et al. Left Ventricular Ejection Fraction Assessment Among Patients with Acute Myocardial Infarction and Its Association with Hospital Quality of Care and Evidence-Based Therapy Use. Circ Cardiovasc Qual Outcomes. 2012;5(5):662-671.
46. **46.** Alexander, KP, Wang TY, Li S, et al. Randomized Trial of Targeted Performance Feedback to Facilitate Quality Improvement in Acute Myocardial Infarction Care. Circ Cardiovasc Qual Outcomes. 2011; 4:129-135.
47. **47.** Xian Y, Chen AY, Thomas L, et al. Sources of Hospital-Level Variation in Major Bleeding Among Patients with Non-ST-Segment Elevation Myocardial Infarction: A Report from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014;7(2):236-243.
48. **48.** Diercks BD, Kontos, MC, Hollander JE, et al. ED administration of thienopyridines in non–ST-segment elevation myocardial infarction: Results from the NCDR. Am J Emerg Med. 2013;31(7):1005-1011.
49. **49.** Mathews R, Fonarow GC, Li S, et al. Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry–Get with The Guidelines. Am Heart J. 2016; 175:1–8.
50. **50.** Enriquez JR, de Lemos JA, Parikh SV, et al. Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. Am Heart J. 2013;165(1):43-9.
51. **51.** Acharjee S, Roe MT, Amsterdam EA, et al. Relation of Admission High-Density Lipoprotein Cholesterol Level and In-Hospital Mortality in Patients with Acute Non-ST Segment Elevation Myocardial Infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2013;112(8):1057-1062.
52. **52.** Wayangankar SA, Roe MT, Chen AY, et al. Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. Indian Heart Journal. 2016;68(4):464-472.
53. **53.** Miller AL, Simon D, Roe MT, et al. Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites with Acute Myocardial Infarction. Am J Cardiol. 2017;119(8):1127–1134.
54. **54.** Riley RF, Newby LK, Don CW, et al. Guidelines-based treatment of anemic STEMI patients: practice patterns and effects on in-hospital mortality: a retrospective analysis from the NCDR. European Heart Journal: Acute Cardiovascular Care. 2013;2(1):35-43.
55. **55.** Shah RV, Holmes D, Anderson M, et al. Risk of Heart Failure Complication During Hospitalization for Acute Myocardial Infarction in a Contemporary Population Insights from the National Cardiovascular Data ACTION Registry. Circ Heart Fail. 2012; 5:693-702.
56. **56.** Udell JA, Wang TY, Li S, et al. Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry. JAMA. 2014;312(8):841-843.
57. **57.** Kontos MC, Scirica BM, Chen AY, et al. Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial

infarction in contemporary practice: A report from the National Cardiovascular Data Registry. Am Heart J. 2015; 169:515-522.

58. **58.** Kontos MC, Rennyson SL, Chen AY, et al. The association of myocardial infarction process of care measures and in-hospital mortality: A report from the NCDR®. Am Heart J. 2014; 0:1-10.
59. **59.** Anstey DE, Li S, Thomas L, et al. Race and Sex Differences in Management and Outcomes of Patients After ST-Elevation and Non-ST-Elevation Myocardial Infarct: Results From the NCDR. Clin Cardiol. 2016;39(10):585-595.
60. **60.** McNamara RL, Wang Y, Partovian C, et al. Development of a Hospital Outcome Measure Intended for Use with Electronic Health Records: 30-Day Risk-standardized Mortality After Acute Myocardial Infarction. Medical Care. 2015; 53:818–826.
61. **61.** Anderson ML, Peterson ED, Peng AS, et al. Differences in the Profile, Treatment, and Prognosis of Patients with Cardiogenic Shock by Myocardial Infarction Classification: A Report from National Cardiovascular Drug Registry. Circ Cardiovasc Qual Outcomes. 2013;6(6):7018-715.
62. **62.** Patel JH, Gupta R, Roe MT, et al. Influence of Presenting Electrocardiographic Findings on the Treatment and Outcomes of Patients with Non-ST-Elevation Myocardial Infarction. Am J Cardiol. 2014;113(2):256–261.
63. **63.** Rousan TA, Pappy RM, Chen AY, et al. Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). Am J Cardiol. 2014;114(8):1136-1144.
64. **64.** Harrison RW, Simon D, Miller AL, et al. Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. Am Heart J. 2016; 178:95-101.
65. **65.** Hall HM, de Lemos JA, Enriquez JR, et al. Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States: Results from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014;11(1).
66. **66.** Rao KK, Enriquez JR, de Lemos JA, et al. Use of aldosterone antagonists at discharge after myocardial infarction: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get with the Guidelines (GWTG). American Heart Journal. 2013;166(4):709-715.
67. **67.** Shen L, Shah BR, Nam A, et al. Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. Am Heart J. 2014;167(6):840-845.
68. **68.** Harskamp RE, Wang TY, Bhatt DL, et al. Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. Am Heart J. 2014;167(3):355-362.
69. **69.** Enriquez JR, Lemos JA, Parikh SV et al. Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes. Circ Cardiovasc Qual Outcomes. 2015;8(6):576-585.
70. **70.** Beatty AL, Li S, Thomas L, et al. Trends in Referral to Cardiac Rehabilitation After Myocardial Infarction: Data from the National Cardiovascular Data Registry 2007 to 2012. JACC. 2014;63(23):2582-2583.
71. **71.** Waldo WS, Brenner DA, Li S, et al. Reperfusion times and in-hospital outcomes among patients with an isolated posterior myocardial infarction: Insights from the National Cardiovascular Data Registry (NCDR). Am Heart J. 2014; 167:350-354.
72. **72.** Karrowni W, Wang TY, Chen AY, et al. Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. Heart. 2014; 101:264-270.
73. **73.** Mumma BE, Kontos MC, Peng SA, et al. Association Between Prehospital ECG Use and Patient Home Distance from the PCI Center on Total Reperfusion Time in STEMI Patients: A Retrospective Analysis from the NCDR. Am Heart J. 2014;167(6):915-920.

74. **74.** Anderson LL, French WJ, Peng SA, et al. Direct Transfer from the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2015;8(9).
75. **75.** Bagai A, Wang Y, Wang TY, et al. In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients with Acute Myocardial Infarction Treated with Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry. Circ Interv. 2014; 7:577-584.
76. **76.** Kang HJ, Simon D, Wang TY, et al. The Contemporary Use of Angiography and Revascularization Among Patients with Non–ST-Segment Elevation Myocardial Infarction in the United States Compared with South Korea. Clin Cardiol. 2015;38(12):708-714.
77. **77.** Wang TY, Vora AN, Peng SA, et al. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients with Reduced Ejection Fraction After Acute Myocardial Infarction. JAHA. 2016;5(1).
78. **78A**. Doll JA, Hellkamp A, Ho PM, et al. Participation in Cardiac Rehabilitation Programs Among Older Patients After Acute Myocardial Infarction. JAMA Int Med. 2015;175(10):1700-1702.
79. **78B**. Doll JA, Hellkamp AS, Goyal A. et al. Treatment and longitudinal of Medicare/Medicaid dual eligible adults with acute MI. JAMA Cardiol. 2016 Oct 1;1(7):787-794. doi: 10.1001/jamacardio.2016.2724.
80. **78C.** Doll JA, Hellkamp A, Thomas L, et al. Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction. Am Heart J. 2015;170(5):855-864.
81. **79.** Hess CN, Peterson ED, Peng SA, et al. Use and Outcomes of Triple Therapy Among Older Patients with Acute Myocardial Infarction and Atrial Fibrillation. JACC. 2015; 66:616–27.
82. **80.** Paixao ARM, Enriquez JR, Wang TY, et al. Risk Factor Burden and Control at the Time of Admission in Patients with Acute Myocardial Infarction: Results from the National Cardiovascular Data Registry. Am Heart J. 2015;170(1):173–179.
83. **81.** Udell, J, Desai, N, Li, S, et al. Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. Circulation: Cardiovascular Quality and Outcomes. 2018.
84. **82.** Shah RU, de Lemos JA, Wang TY, et al. Post-Hospital Outcomes of Patients with Acute Myocardial Infarction with Cardiogenic Shock Findings From the NCDR. JACC. 2016;67(7):739-747.
85. **83.** Sutton NR, Li S, Thomas L, et al. The Association of Left Ventricular Ejection Fraction with Clinical Outcomes after Myocardial Infarction: Findings from the ACTION Registry-GWTG Medicare Linked Database. Am Heart J. 2016; 178:65-73.
86. **85.** Pandey A, McGuire DK, de Lemos JA, et al. Revascularization Trends in Patients with Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting with Non-ST Elevation Myocardial Infarction: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG). Circ Cardiovasc Qual Outcomes. 2016; 9:197-205.
87. **93.** Dasari TW, Hamilton S, Chen AY, et al. non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR). Am Heart J. 2016; 172:1-8.
88. **94.** Hess CN, Hellkamp AS, Roe MT, et al. Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients with Non–ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. JAHA. 2016;5(3).
89. **95.** Goyal A, de Lemos JA, Peng SA, et al. Association of Patient Enrollment in Medicare Part D with Outcomes After Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2015; 8(6):567-575.

90. **96.** Vora AN, Peterson ED, Hellkamp AS, et al. Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. Circ Cardiovasc Qual Outcomes. 2016; 115.002108
91. **97A.** Pokorney SD, Miller AL, Chen AY, et al. Implantable Cardioverter-Defibrillator Use Among Medicare Patients with Low Ejection Fraction After Acute Myocardial Infarction. JAMA. 2015;313(24):2433-2440.
92. **97B**. Pokorney SD, Miller AL, Chen AY, et al. Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients with Low Ejection Fraction After Myocardial Infarction. Circulation. 2017; 135:38–47.
93. **98.** Diercks DB, Kontos MC, Chen AY, et al. Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC. 2009;53(2):161-6.
94. **99.** Gruberg L, Hellkamp AS, Thomas LE, et al. The Association of Previous Revascularization with In-Hospital Outcomes in Acute Myocardial Infarction Patients: Results from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2015;8(15):1954-1962.
95. **100.** Doll JA, Li S, Chiswell K, et.al. Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. Eur Heart J. 2018;39(3):193-200.
96. **101**. Mody P, Wang T, McNamara R, et al. Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction. Eur Hear J Quality Care Clinical Outcomes. 2018;4(1):43-50.
97. **111.** Faridi KF, Peterson ED, McCoy LA, et al. Timing of First Post-Discharge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiol. 2016;1(2):147-155.
98. **118.** Vora AN, Wang TY, Li S, et al. Selection of Stent Type in Patients with Atrial Fibrillation Presenting with Acute Myocardial Infarction: An Analysis from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry—Get with the Guidelines. JAHA. 2017;6(8).
99. **122.** Badri M, Abdelbaky A, Li S, et al. Pre catheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights from the National Cardiovascular Data Registry. JAHA. 2017;6(9).
100. **123.** Roswell RO, Kunkes J, Chen AY, et al. Impact of Sex and Contact-to-Device Time on Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction—Findings from the National Cardiovascular Data Registry. JAHA. 2017;6(1).
101. **126**. M. Kontos. Association of acute myocardial infarction cardiac arrest patient volume and in-hospital mortality in the United States: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry. Clin Cardiol. 2019
102. **127A**. Fordyce C, Cohen M. et al. Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction. Journal of Thrombosis and Thrombolysis. 2016.
103. **127B**. Fordyce CB, Wang TY, Chen AY, et al. Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction with and Without Out-of-Hospital Cardiac Arrest. J Am Coll Cardiol. 2016;67(17):1981-1990.
104. **131.** Vora AN, Wang TY, Hellkamp AS, et al. Differences in Short-and Long-Term Outcomes Among Older Patients with ST-Elevation Versus Non-ST-Elevation Myocardial Infarction with Angiographically Proven Coronary Artery Disease. Circ Cardiovasc Qual Outcomes. 2016; 9:513-522.
105. **132**. Hansen, et al. Contemporary Pattern of Invasive Strategies for Patients with Non-ST elevation Myocardial Infarction: Insights from NCDR ACTION-GWTG. JACC Cardivasc Interv.

106. **133.** Basra, S, Wang, T, Simon, D, et al. Ticagrelor Use in Acute Myocardial Infarction: Insights from the National Cardiovascular Data Registry. Journal of the American Heart Association. 2018.
107. **134**. Smilowitz NR, Mahajan AM, Roe MT, et al. Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines). 2017;10(12): e003443.
108. **143.** Fanaroff AC, Peterson ED, Chen AY, et al. Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized with Non-ST-Segment Elevation Myocardial Infarction. JAMA Cardiology. 2017;2(1):36-44.
109. **137A.** Fanaroff AC, Peterson ED, Chen AY, et al. Contemporary practices regarding location of care in NSTEMI, implications for resource utilization and patient outcomes; JAMA Cardiology; 2017;2(1):36-44
110. **137B.** Yi Pi, Roe MT, Homes DN, et al. Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting (CABG) Trends in Patients with ST-elevation Myocardial Infarction: Results from the National Cardiovascular Data Registry ACTION Registry–GWTG. Circ Cardiovasc Qual Outcomes. 2017;10(8).
111. **141**. Rymer JA, Chen AY, Thomas L, et al. Outcomes Comparison Between Patients with Post-Myocardial Infarction Outpatient Care Delivered by Physicians versus Non-Physician Providers. Journal of the American Heart Association. 2018;7: e00848
112. **143.** Fanaroff A, Chen A, Thomas L, et al. Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults with Non–ST-Segment–Elevation Myocardial Infarction. JAHA. 2018.
113. **144.** Doll JA, Hellkamp AS, Goyal A, et al. Treatment, Outcomes, and Adherence to Medication Regimens Among Dual Medicare-Medicaid–Eligible Adults with Myocardial Infarction. JAMA Cardiology. 2016;1(7):787-794.
114. **148.** Neeland IJ, Das SR, Simon DN, et al. The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR. Eur Hear J Quality Care Clinical Outcomes. 2017;3(3):183-191.
115. **156.** Pandey A, Golwala H, Hall HM, et al. Association of US Centers for Medicare and Medicaid Services Hospital 30-day Risk-Standardized Readmission Metric with Care Quality and Outcomes After Acute Myocardial Infarction: Findings from the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines. JAMA Cardiology. 2017;2(7):723-731.
116. **158.** Desai N, Udell J, Wang Y, et al. Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. Circ Cardiovasc Qual Outcomes. 2019;12: e004983. DOI: 10.1161
117. **162.** Guimaraes P, Zakroyski P, Gpoyal A, et al. Usefulness of Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Myocardial Infarction. AJC. 2018 September 26.
118. **166.** McNamara RL, Kennedy KF, Cohen DJ, et al. Predicting In-Hospital Mortality in Patients with Acute Myocardial Infarction. J Am Coll Cardiol. 2016;68(6):626-635.
119. **167.** Desai NR, Kennedy KF, Cohen DJ, et al. Contemporary risk model for in hospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry - Get with The Guidelines (GWTG). Am Heart J. 2017;194(0):16-24.
120. **176A.** Paixao A, Enriquez JR, Wang TY, et al. Risk Factor Burden and Control at the Time of Admission in Patients with Acute Myocardial Infarction: Results from the NCDR. Am Heart J. 2015;170(1):173-179.
121. **180.** Udell, J, Desai, N, Li, S, et al. Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. Circulation: Cardiovascular Quality and Outcomes. 2018.

122. **181**. Dharmarajan K, McNamara RL, Wang Y, et al. Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. Ann Intern Med. 2017;167(8):555-564.
123. **186.** Bagai A, Lu D, Lucas J, et al. Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report from the NCDR Chest Pain–MI Registry. JAHA. 2018.
124. **190.** Fordyce C, Wang T, Chen A, et al. Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction with and Without Out-of-Hospital Cardiac Arrest. JACC. 2016.
125. **205.** Udell JA, Lu D, Bagai A, et al. Preexisting Frailty and Outcomes in Older Patients with Acute Myocardial Infarction. AHJ. Mar 24, 2022.
126. **214.** John A Dodson, Judith Hochman, Matthew T Roe, Anita Chen et al. The Association of Frailty with In-Hospital Bleeding Among Older Adults with Acute Myocardial Infarction: Insights from the Action Registry-G. Circulation. 2018;136: A15096
127. **216.** Feldman D, Wang T, Chen A, et al. In-Hospital Bleeding Outcomes of Myocardial Infarction in the Era of Warfarin and Direct Oral Anticoagulants for Atrial Fibrillation in the United States: A Report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry. Journal of the American Heart Association. 2019. DOI: 10.1161
128. **219.** Bagai A, Chen A, Udell J, et al. Association of Cognitive Impairment with Treatment and Outcomes in Older Myocardial Infarction Patients: A Report from the NCDR Chest Pain–MI Registry. J Am Heart Assoc. 2019;8: e012929. DOI: 10.1161
129. **236.** Rymer J, Chen A, Thomas L, et al. Readmissions After Acute Myocardial Infarction: How Often Do Patients Return to the Discharging Hospital? Am Heart Assoc. 2019;8: e012059.
130. **238.** Pagidipati NJ, Hellkamp A, Thomas L. Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. JAMA Cardiol. 2017;2(9):1040-1042.
131. **247.** Xuming Dai, Jan Busby-Whitehead, Karen P Alexander et al. Cardiac catheterization laboratory pre-activation and time-to-treatment for primary PCI: Insights from the ACTION GWTG-Registry. J Geriatr Cardio. 2016 Feb; 13(2): 101–108.
132. **258.** Rodriguez F, Chung S, Blum MR, et al. Atherosclerotic Cardiovascular Disease Risk Prediction in Disaggregated Asian and Hispanic Subgroups Using Electronic Health Records. JAHA. 2019 Jul 11.
133. **259.** Wadhera R, Vhatt D, Joynt Maddox K, et al. Association of State Medicaid Expansion with Quality of Care and Outcomes for Low-Income Patients Hospitalized with Acute Myocardial Infarction. JAMA Card. 2018.
134. **261.** Fanaroff AC, Chen A, Diepen S et al. Association Between Intensive Care Unit Usage and Long-Term Medication Adherence, Mortality, and Readmission Among Initially Stable Patients with Non–ST-Segment–Elevation Myocardial Infarction. J Am Heart Assoc. 2020;9: e015179. DOI: 10.1161/JAHA.119.015179
135. **264.** Kini, V, Peterson, PN, Spertus, JA, et al Clinical Model to Predict 90-Day Risk of Readmission After Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2018.
136. **265.** Wasfy, J, Kennedy, K, Masoudi, F et al. Predicting Length of Stay and the Need for Postacute Care After Acute Myocardial Infarction to Improve Healthcare Efficiency A Report from the National Cardiovascular Data Registry's ACTION Registry. Circulation: Cardiovascular Quality and Outcomes. 2018.
137. **266**. Wasfy JH, Kennedy KF, Masoudi FA, et al. Predicting Length of Stay and the Need for Postacute Care After Acute Myocardial Infarction to Improve Healthcare Efficiency A Report from the National Cardiovascular Data Registry's ACTION Registry. Circ: CQO. 2018

138. **277**. Goldstein SA, Li S, Lu D, et al. Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age with a Low Ejection Fraction After Coronary Revascularization. Am J Cardiol. 2021.
139. **279**. Pandey A, Keshvani N, Khera R et al. Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries. JAMA Cardiology.2020.
140. **286.** Mahajan AM, Gandhi H, Smilowitz NR, et al. Seasonal and circadian patterns of myocardial infarction by coronary artery disease status and sex in the ACTION Registry-GWTG. Int J Cardiol. 2019; 274:16-20. doi: 10.1016/j.ijcard.2018.08.103
141. **297**. Faridi, K, Garratt, K, Kennedy, K et al. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circ Cardiovasc Qual Outcomes. 2020;13: e006275
142. **300.** Haghighat L, Reinhardt S, Saly D, et al. Comfort Measures Only in Myocardial Infarction: Prevalence of This Status, Change Over Time, and Predictors from a Nationwide Study. Circ Cardiovasc Qual Outcomes. 2022 Jan.
143. **349**. Gandhi S, Garratt K, Li S, et al. Ten-Year Trends in Patient Characteristics, Treatments, and Outcomes in Myocardial Infarction from National Cardiovascular Data Registry Chest Pain-MI Registry. Circ Cardiovasc Qual Outcomes. 2022 Jan.
144. **364**. Peacock WF, Levy PD, Diercks DB, et al. The Impact of American College of Cardiology Chest Pain Center Accreditation on Guideline Recommended Acute Myocardial Infarction Management. Crit Pathw Cardiol. 2021 Dec; 20(4):173-178
145. **387.** Wu, C, Albert, N, Gluckman, T et al. Facilitating the identification of patients hospitalized for acute myocardial infarction and heart failure and the assessment of their readmission risk through the Patient Navigator Program. American Heart Journal.2020
146. **408.** Khera, R, Haimovich, J, Hurley, N et al. Use of Machine Learning Models to Predict Death After Acute Myocardial Infarction. JAMA Cardiol. 2021.01 22.

IN PRESS

1. **365.** Elgendy I. Sex-specific Differences in In-hospital Management and Outcomes of Patients with Acute Myocardial Infarction and Cardiogenic Shock: An Analysis from the Chest Pain Registry. JACC Cardiovasc Interv. 2022. In Press.

Diabetes Collaborative Registry Publications

PUBLISHED

1. **2.** Tinsley L, Wong ND, Reusch JEB, et al. Regional differences in the management of cardiovascular risk factors among adults with diabetes: An evaluation of the Diabetes Collaborative Registry. J Diabetes Complications. 2020 Aug;34(8):107591. doi: 10.1016/j.jdiacomp.2020.107591.
2. **4.** Fan, Wenjun, Yang Song, Silvio E. Inzucchi, Laurence Sperling, Christopher P. Cannon, Suzanne V. Arnold, Mikhail Kosiborod, and Nathan D. Wong. "Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry." Diabetes, Obesity and Metabolism (2019).
3. **9.** Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam CSP, Sperling LS, Kosiborod M. Understanding Contemporary Use of Thiazolidinediones. An Analysis from the Diabetes Collaborative Registry. Circ Heart Fail. 2019;12
4. **11 & 15.** Wittbrodt E, Bhalla N, Sundell KA, et al. Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry. Endocrynology, Diabetes, & Metabolism. 2020.
5. **19.** Wittbrodt E, Chamberlain D, Arnold S, et al. Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry. Diabetes Obes Metab. 2019 Aug;21(8):1985-1989. doi: 10.1111/dom.13738.
6. **20.** Arnold, S.V.; Lipska, K.J., Wang, J. et al. Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus. Journal of the American Geriatrics Society. (2018 Apr 10). doi:10.1111/jgs.15335
7. **21**. Arnold SV, McGuire DK, Inzucchi SE, Tang F, Mehta SN, Lam CSP, Goyal A, Sperling LS, Wong ND, Hammar N, Fenici P, Kosiborod M. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). J Diabetes Complications. 2018.
8. **22**. Arnold, S.V.; Goyal, A.; Inzucchi, S.E. et al. Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry®. Journal of the American Heart Association. 2017; 6(8): https://doi.org/10.1161/JAHA.117.005999.
9. **23**. Arnold SV, Kosiborod M, Wang J, Fenici P, Gannedahl G, LoCasale RJ. Burden of cardio-renalmetabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab. 2018; 1–4. https://doi.org/10.1111/dom.13303.
10. **24**. Arnold SV, Echouffo-Tcheugui J, Lam CSP, Inzucchi SE, Tang F, McGuire DK, Goyal A, Maddox TM, Sperling LS, Fonarow GC, Masoudi FA, Kosiborod M. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). Am Heart J. 2018.
11. **26**. Arnold, S.V.; Inzucchi, S.E.; McGuire, D.K. et al. Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients with Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. Diabetes Care. 2016, Jul; 39(7): e99-e101.
12. **27.** Arnold SV, Gosch K, Wong ND, et al. Use of Non-LDL-C Lipid-Lowering Medications in Patients with Type 2 Diabetes. Endocrinol Diabetes Metab. 2020 Jul; 3(3): e00126.
13. **29**. Koehn D, Repetto E, Brookes-Smith I, et al. Second line glucose lowering treatment therapies as chosen by cardiologists vs non- cardiologists: an analysis of the Diabetes Collaborative Registry (DCR). EASD. 2018.
14. **34.** Suzanne AV, Jones P, Beasley M, et al. Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry. Cardiovasc Diabetol (2020) 19:212.
15. **N/A**. Arnold, SV; McGuire, DK; Inzucchi, SE, et al. Assessing the Use of Patient-Focused Pharmacotherapy in Glycemic Management Through the Diabetes Collaborative Registry (DCR). Journal of Diabetes and Its Complications. 2018 Aug 09.
16. **N/A**. Arnold, SV; Yap,J; Lam CSP, et al. Management of patients with diabetes and heart failure with

reduced ejection fraction: an international comparison. Diabetes, Obesity and Metabolism. 2019 Feb;21(2):261-266. doi: 10.1111/dom.13511.

IN PRESS

PUBLISHED

1. **1.** Farmer SA, Kirkpatrick JN, Heidenreich PA, et al. Ethnic and racial disparities in cardiac resynchronization therapy. Heart Rhythm. 2009 Mar; 6(3):325-31.
2. **2.** Lampert R, Wang Y, Curtis J. Variation among hospitals in selection of higher-cost, "higher-tech," implantable cardioverter-defibrillators: Data from the National Cardiovascular Data Registry (NCDR) Implantable Cardioverter/Defibrillator (ICD) Registry. Am Heart J. Feb 2013.
3. **3.** Peterson PN, Daugherty SL, Wang Y, et al. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. CIRC. 2009 Mar 3; 119(8):1078-84.
4. **4.** Daugherty SL, Peterson PN, Wang Y, et al. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria? Am Heart J. 2009 Aug; 158(2):224-9.
5. **5.** Freeman JV, Wang Y, Curtis JP, et al. The Relation Between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation from the Implantable Cardioverter-Defibrillator Registry Original Research Article. JACC. September 2010.
6. **6.** Freeman JV, Wang Y, Curtis JP, et al. Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation. CIRC. 2012; 125 57-64.
7. **7.** Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA. 2009 Apr 22; 301(16):1661-70.
8. **8.** Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA. 2011 Jan 5; 305(1):43-9.
9. **9.** Al-Khatib SM, Hellkamp A, Bardy GH, et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013 Jan 2; 309(1):55-62.
10. **10.** Al-Khatib S, Hellkamp A, Fonarow G, et al. Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients with Left Ventricular Ejection Fraction Between 30% and 35%. JAMA. 2014; 311(21):2209-2215.
11. **11.** Pun PH, Hellkamp AS, Sanders GD, et al. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. Nephrol Dial Transplant. 2014. doi: 10.1093/ndt/gfu274.
12. **12.** Zeitler EP, Hellkamp AS, Fonarow GC, et al. Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JCHF. 2015; 3(2): 159-167.
13. **13.** Pokorney SD, Hellkamp AS, Yancy CW, et al. Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. Circ Arrhythmia Electrophysiol. 2015; 8: 145-151.
14. **14.** Hess PL, Mi X, Curtis LH, et al. Follow-up of patients with new cardiovascular implantable electronic devices: Is adherence to the experts' recommendations associated with improved outcomes? Heart Rhythm. August 2013, Volume 10(8): 1127–1133. doi: 10.1016/j.hrthm.2013.06.009.
15. **15.** Hess PL, Hellkamp AS, Peterson ED, et al. Survival after Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients with Chronic Kidney Disease. Circ Arrhythm Electrophysiol. 2014; 7: 793-799.
16. **16.** Dewland TA, Pellegrini CN, Wang Y, et al. Dual-Chamber Implantable Cardioverter-Defibrillator Selection Is Associated with Increased Complication Rates and Mortality Among Patients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. JACC. 2011.
17. **17.** Matlock DD, Peterson PN, Heidenreich PA, et al. Regional Variation in the Use of Implantable

Cardioverter-Defibrillators for Primary Prevention: Results from the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2011;4;114-121.

18. **18.** Aggarwal A, Wang Y, Rumsfeld JS, et al. Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. Heart Rhythm. 2009 Nov.
19. **19.** Tsai V, Goldstein MK, Hsia HH, et al. Age Differences in Primary Prevention Implantable Cardioverter-Defibrillator Use in U.S. Individuals. J Am Geriatr Soc. 2011.
20. **20.** Matlock DD, Kutner JS, Emsermann CB, et al. Regional Variations in Physicians' Attitudes and Recommendations Surrounding Implantable Cardioverter-Defibrillators. Journal of Cardiac Failure. 2011.
21. **21.** Schneider PM, Pellegrini CN, Wang Y et al. Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008. Am J Cardiol. 2014.
22. **22.** Fein AS, Wang Y, Curtis JP, et al. Prevalence and Predictors of Off-Label Use of Cardiac Resynchronization Therapy in Patients Enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry Original Research Article. JACC. 2010.
23. **23.** Ghanbari H, Nallamothu BK, Wang Y, et al. Antithrombotic Therapy and Outcomes After ICD Implantation in Patients with Atrial Fibrillation and Coronary Artery Disease: An Analysis from the National Cardiovascular Data Registry (NCDR)®. J Am Heart Assoc. 2015; 4: e001331.
24. **24.** Haines DE, Wang Y, Curtis J, et al. Implantable Cardioverter-Defibrillator Registry Risk Score Models for Acute Procedural Complications or Death After Implantable Cardioverter-Defibrillator Implantation. CIRC. 2011; 123:2069-2076.
25. **25.** Hammill SC, Phurrough S, Brindis R, et al. The National ICD Registry: Now and into the future. Heart Rhythm. 2006.
26. **26.** Hammill SC, Stevenson LW, Kadish AH, et al. Review of the Registry's First Year, Data Collected, and Future Plans. Heart Rhythm. September 2007; Vol. 4, Issue 9, Pages 1260-1263.
27. **27.** Hammill SC, Kremers MS, Stevenson LW, et al. Review of the Registry's Second Year, Data Collected, and Plans to Add Lead and Pediatric ICD Procedures. Heart Rhythm. September 2008; Vol. 5, Issue 9, Pages 1359-1363.
28. **28.** Kaiser DW, Tsai V, Heidenreich, PA, et al. Defibrillator Implantations for Primary Prevention in the United States: Inappropriate Care or Inadequate Documentation? Insights from the National Cardiovascular Data ICD Registry. HRJ. 2015.
29. **29.** Tsai V, Goldstein MK, Hsia HH, et al. Influence of Age on Perioperative Complications Among Patients Undergoing Implantable Cardioverter-Defibrillators for Primary Prevention in the United States. Circ Cardiovasc Qual Outcomes. 2011; 4:549-556.
30. **30.** Cheng A, Wang Y, Curtis JP, et al. Acute lead dislodgements and in-hospital mortality in patients enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry. J Am Coll Cardiol. 2010 Nov 9;56(20):1651-6.
31. **31.** Farmer SA, Tuohy EJ, Small DS, et al. Impact of Community Wealth on Use of Cardiac-Resynchronization Therapy with Defibrillators for Heart Failure Patients. Circ Cardiovasc Qual Outcomes. 2012 Nov; 5(6):798-807.
32. **32.** Cheng A, Wang Y, Berger RD et al. Electrophysiology Studies in Patients Undergoing ICD Implantation: Findings from the NCDR®. Pacing Clin Electrophysiol. 2012 Aug; 35(8):912-8.
33. **33.** Wei S, Loyo-Berríos NI, Haigney MC, et al. Elevated B-Type Natriuretic Peptide Is Associated with Increased In-Hospital Mortality or Cardiac Arrest in Patients Undergoing Implantable Cardioverter-

Defibrillator Implantation. Circ Cardiovasc Qual Outcomes. 2011 May; 4(3):346-54.

34. **34.** Hammill SC, Kremers MS, Kadish AH, et al. Review of the ICD Registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance. Heart Rhythm. 2009 Sep; 6(9):1397-401.
35. **35.** Bhatt P, Curtis J, Wang Y, et al. Impact of a Recent Lead Recall on Utilization of Implantable Cardioverter Defibrillators: Data from the NCDR ICD Registry™. J Cardiovasc Electrophysiol. 2012 Aug; 23(8):861-5.
36. **36.** Matlock DD, Peterson PN, Wang Y, et al. Variation in Use of Dual-Chamber Implantable Cardioverter-Defibrillators: Results from the National Cardiovascular Data Registry. Arch Intern Med. 2012; 172(8):634-641.
37. **37.** Miller AL, Wang Y, Curtis J, et al. Optimal Medical Therapy Use Among Patients Receiving Implantable Cardioverter/Defibrillators: Insights from the National Cardiovascular Data Registry. Arch Intern Med. 2012 Jan 9; 172(1):64-7.
38. **38.** Hammill SC, Kremers MS, Stevenson LW, et al. Review of the Registry's Fourth Year, Incorporating Lead Data and Pediatric ICD Procedures, and Use as a National Performance Measure Original Research Article. Heart Rhythm. 2010 Sep; 7(9):1340-5.
39. **39.** Eapen ZJ, Al-Khatib S, Lopes RD, et al. Are Racial/Ethnic Gaps in the Use of Cardiac Resynchronization Therapy Narrowing? An Analysis of 107,096 Patients From the National Cardiovascular Data Registry's ICD Registry. J Am Coll Cardiol. 2012 Oct 16; 60(16):1577-8.
40. **40.** Dodson JA, Lampert R, Wang Y, et al. Temporal Trends in Quality of Care among ICD Recipients: Insights from the NCDR®. Circulation. 2014; 129:580-586.
41. **41A.** Hsu JC, Varosy PD, Bao H, et al. Low Body Mass Index but Not Obesity is Associated with In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients: Insights from the NCDR®. J Am Heart Assoc. 2012.
42. **41B.** Nishimura M, Marcus GM, Varosy PD, et al. Association of Body Mass Index with Cardiac Resynchronization Therapy Intention and Left Ventricular Lead Implantation Failure: Insights from the NCDR Implantable Cardioverter-Defibrillator Registry. J Interv Card Electrophysiol. 2019.
43. **42.** Russo AM, Wang Y, Al-Khatib SM, et al. Patient, Physician, and Procedural Factors Influencing the Use of Defibrillation Testing during Initial Implantable Cardioverter Defibrillator Insertion: Findings from the NCDR. PACE. 2013 Aug 26. doi: 10.1111.
44. **43.** Hsu JC, Marcus GM, Al-Khatib SM, et al. Predictors of an Inadequate Defibrillation Safety Margin at ICD Implantation. J Am Coll Cardiol. 2014; 64:256–64.
45. **44.** Akar JG, Bao H, Jones P, et al. Use of Remote Monitoring of Newly Implanted Cardioverter-Defibrillators: Insights from the Patient Related Determinants of ICD Remote Monitoring (Predict RM) Study. Circulation. September 16, 2013. doi: 10.1161/CIRCULATIONAHA.113.002481.
46. **46.** Russo AM, Daugherty SL, Masoudi FA, et al. Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). Am Heart J. 2015; 170 (2): 330-8.
47. **47.** Peterson PN, Varosy PD, Heidenreich PA, et al. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA. 2013 May 15; 309(19):2025-34.
48. **48.** Heidenreich PA, Tsai V, Curtis J, et al. A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement. Am Heart J. 2015; 170 (2): 281-289.e2.
49. **49.** Heidenreich PA, Tsai V, Bao H, et al. Does Age Influence Cardiac Resynchronization Therapy Use and

Outcome? JACC HF. 2015; 3(6): 497–504.

50. **50.** Prutkin JM, Reynolds MR, Bao H, et al. Rates of and Factors Associated with Infection in 200,909 Medicare Implantable Cardioverter-Defibrillator Implants: Results from the NCDR. Circulation. 2014; 130:1037-1043.
51. **51.** Peterson PN, Greiner MA, Qualls LG, et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. JAMA. 2013 Aug 14; 310(6):617-26. doi: 10.1001/jama.2013.8641.
52. **52.** Khazanie P, Hammill BG, Qualls LG, et al. Clinical Effectiveness of Cardiac Resynchronization Therapy vs Medical Therapy Alone Among Patients with Heart Failure: Analysis of the ICD Registry and ADHERE. Circulation: Heart Failure. 2014; 7: 926-934.
53. **53.** Kremers MS, Hammill SC, Berul CI, et al. The National ICD Registry Report: Version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm. April 2013. Volume 10, Issue 4: Pages e59-e65.
54. **54.** Kramer DB, Kennedy KF, Noseworthy PA, et al. Characteristics and Outcomes of Patients Receiving New and Replacement Implantable Cardioverter-Defibrillators: Results From the NCDR. Circ Cardiovasc Qual Outcomes. 2013 July, 6(4): 488-497.
55. **55.** Steckman D, Varosy PD, Parzynski CS, et al. In-Hospital Complications Associated with Reoperations of Implantable Cardioverter Defibrillators. American Journal of Cardiology. Aug 1, 2014. 114(3): 419-426.
56. **57A.** Hsu JC, Varosy PD, Bao H, et al. Cardiac Perforation from Implantable Cardioverter-Defibrillator Lead Placement: Insights From the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2013; 6: 582-590.
57. **57B.** Hsu JC, Varosy PD, Bao H, et al. Coronary Venous Dissection from Left Ventricular Lead Placement During Cardiac Resynchronization Therapy with Defibrillator Implantation and Associated in-Hospital Adverse Events (from the NCDR ICD Registry). Am J Cardiol. 2018 Jan 1; 121(1):55-61. doi: 10.1016/j.amjcard.2017.09.019.
58. **58.** Dev S, Peterson PN, Wang Y, et al. Prevalence, Correlates, and Temporal Trends in Antiarrhythmic Drug Use at Discharge After Implantable Cardioverter Defibrillator Placement from the National Cardiovascular Data Registry (NCDR). Am J Cardiol. 2014; 113:314e320.
59. **59A.** Zusterzeel R, Curtis JP, Caños DA, et al. Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving CRT: Results From the NCDR. JACC. 2014; 64(9):887.
60. **59B.** Zusterzeel R, Spatz ES, Curtis JP, et al. Cardiac Resynchronization Therapy in Women Versus Men; Observational Comparative Effectiveness Study from the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015; 8: S4-S11.
61. **60.** Hsu JC, Varosy PD, Parzynski CS, et al. Procedure timing as a predictor of in hospital adverse outcomes from implantable cardioverter-defibrillator implantation: Insights from the National Cardiovascular Data Registry. Am Heart J. 2015; 169 (1): 45-52. e3.
62. **61.** Borne RT, Peterson PN, Greenlee R, et al. Temporal Trends in Patient Characteristics and Outcomes Among Medicare Beneficiaries Undergoing Primary Prevention Implantable Cardioverter-Defibrillator Placement in the United States, 2006–2010: Results from the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. CIRC. 2014; 130 (10): 845-853.
63. **62.** Jordan CP, Freedenberg V, Wang Y, et al. Implant and Clinical Characteristics for Pediatric and Congenital Heart Patients in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. Circ Arrhythmia Electrophysiol. 2014. doi: 10.1161/CIRCEP.114.001841 http://circep.ahajournals.org/content/7/6/1092.abstract.
64. **63.** Sood N, Martin DT, Lampert R, et al. Incidence and Predictors of Perioperative Complications with

Transvenous Lead Extractions: Real World Experience with NCDR Registry. Circulation: Arrhythmia and Electrophysiology. 2018; 11: e004768.

65. **64.** Hess PL, Greiner MA, Al-Khatib SM, et al. Same-Day Discharge and Risks of Mortality and Readmission After Elective ICD Placement for Primary Prevention. J Am Coll Cardiol. 2015; 65(9):955-957.
66. **65.** Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2013; 61:1318–68.
67. **66.** Dodson JA, Reynolds MR, Bao H, et al. Developing a Risk Model for in-Hospital Adverse Events following ICD Implantation: A Report from the NCDR® Registry. Journal of the American College of Cardiology. 2013. doi: 10.1016/ j. jacc.2013.09.079.
68. **67.** Masoudi FA, Go AS, Magid DJ, et al. Age and Sex Differences in Long-Term Outcomes Following Implantable Cardioverter-Defibrillator Placement in Contemporary Clinical Practice: Findings from the Cardiovascular Research Network. J Am Heart Assoc. 2015; 4: e002005.
69. **68.** Masoudi FA, Go AS, Magid DJ, et al. Longitudinal Study of Implantable Cardioverter-Defibrillators: Methods and Clinical Characteristics of Patients Receiving Implantable Cardioverter-Defibrillators for Primary Prevention in Contemporary Practice. Circ Cardiovasc Qual Outcomes. 2012 Nov; 5(6): e78-85.
70. **69.** Masoudi FM, Mi X, Curtis LH, et al. Comparative Effectiveness of Cardiac Resynchronization Therapy with an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone. Ann Intern Med. 2014; 160:603-611.
71. **70.** Setoguchi S, Warner L, Stewart GC, et al. Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure. BMJ. 2014; 348: g2866.
72. **71.** Chen C, S LW, Stewart GC, et al. Real-world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure. BMJ. 2015; 351:h3529.
73. **73.** Gleva MJ, Wang Y, Curtis JP, et al. Complications Associated with Implantable Cardioverter Defibrillators in Adult Congenital Heart Disease: Insights from the NCDR. Am J Cardiol. 2017.
74. **74**. Green A, Leff B, Wang Y, et al. Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death: Prevalence and Impact on Mortality. Circ Cardiovasc Qual Outcomes. 2016 Jan; 9(1):23-30.
75. **75**. Khazanie P, et al. Use and Outcomes of Cardiac Resynchronization Therapy among Patients with Heart Failure and Atrial Fibrillation. Submitted title: Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients with Heart Failure and Atrial Fibrillation: Findings from the NCDR ICD Registry. Circ HF.
76. **76**. Kramer DB, Kennedy KF, Spertus JA, et al. Mortality Risk Following Replacement Implantable Cardioverter-Defibrillator Implantation at End of Battery Life: Results from the NCDR®. Heart Rhythm. February 2014.
77. **78**. Ranasinghe I, Parzynski CS, Freeman JV, et al. Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study. Ann Intern Med. 2016 May 3.
78. **79**. Friedman D, Singh J, Curtis J, et al. Comparative Effectiveness of Cardiac Resynchronization Therapy

with Defibrillator versus Defibrillator Alone in Heart Failure Patients with Moderate to Severe Chronic Kidney Disease. JACC. 2015; 65(10S).

79. **83**. Pokorney SD, Parzynski CS, et al. Temporal Trends in and Factors Associated with Use of Single Versus Dual Coil ICD Leads: Data from the NCDR ICD Registry. JACC: EP Clinical Electrophysiology. 2017.
80. **88A**. Akar JG, Bao H, Jones P, et al. Use of Remote Monitoring Is Associated with Lower Risk of Adverse Outcomes Among Patients with Implanted Cardiac Defibrillators. Circ EP. 2015.
81. **88B**. Khazanie P, Hellkamp AS, Fonarow GC, et al. Association Between Comorbidities and Outcomes in Heart Failure Patients with and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. J Am Heart Assoc. 2015;4: e002061.
82. **93.** Zeitler EP, Wang Y, Dharmarajan K, et al. Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explanation for Unused or Malfunctioning Leads: A Report from the National Cardiovascular Data Registry. Circ Arrhythm Electrophysiol. 2016 Jul; 9(7).
83. **94.** Katz DF, Peterson P, Borne RT, et al. Survival After Secondary Prevention ICD Placement: An Analysis from the NCDR ICD Registry. JACC: EP. January 2017.
84. **96**. Betz J, Katz DF, Peterson PN, et al. Outcomes of Older Patients Receiving Secondary Prevention ICDs: An Analysis from the NCDR ICD Registry. JACC. January 2017.
85. **98.** Borne RT, Randolph TC, Wang Y, et al. Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA. Network.Open.2019;2(10): e1913553.doi:10.1001/jamanetworkopen.2019.13553.
86. **100**. Echouffo-Tcheugui JB, Masoudi FA, Bao H, Spatz ES, et al. Diabetes and Outcomes of Cardiac Resynchronization with Implantable Cardioverter Defibrillator Therapy in Older Patients with Heart Failure. Circ Arrhythmia Electrophysiology. 2016 Aug; 9(8). pii: e004132.
87. **101**. Friedman DJ, Parzynski CS, Varosy PD, et al. Trends and in-hospital outcomes associated with early adoption of the subcutaneous ICD in the US. JAMA Cardiol. 2016 Nov 1;1(8):900-911.
88. **102**. Marzec LN, Peterson PN, Bao H, et al. Use of CRT among Eligible Patients Receiving an ICD: Insights from the NCDR ICD Registry. JAMA Cardiol. 2017 May 1; 2(5):561-565.
89. **104**. Bilchick KC, Wang Y, Cheng A, et al. Seattle Heart Failure Model and Seattle Proportional Risk Model Together Identify Patients Most Likely to Benefit from Primary Prevention ICDs. J Am Coll Cardiol. 2017 May 30;69(21):2606-2618.
90. **104B.** Bilchick KC, Wang Y, Curtis JP, et al. Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. AHJ. 2020.
91. **107.** Annapureddy AR, Henien S, Wang Y, et al. Association Between Industry Payments to Physicians and Device Selection: A Report from the NCDR ICD Registry. JAMA. 2020; 324(17):1755-1764.
92. **109.** Ahmed I, Merchant F, Curtis J, et al. Impact of Insurance Status on ICD Implantation Practice Patterns: Insights from the NCDR ICD Registry. AHJ. 2021.
93. **110**. Kipp R, Hsu JC, Freeman J, et al. Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. Heart Rhythm. 2017.
94. **121**. Friedman DJ, Bao H, Spatz ES, et al. The Association between a Prolonged PR Interval and Outcomes of CRT: a Report from the NCDR. Circulation. 2016; 134:1617-1628.
95. **123**. Peterson PN, Greenlee RT, Go AS, et al. Inappropriate Shocks with Single versus Dual Chamber ICDs for Primary Prevention: Results from the Cardiovascular Research Network Longitudinal Study of ICDs. J Am Heart Assoc. 2017 Nov 9; 6(11). pii: e006937. doi: 10.1161/JAHA.117.006937.
96. **124.** Bansal N, Szpiro A, Masoudi F, et al. Kidney function and appropriateness of device therapies in adults

with implantable cardioverter defibrillators. Heart (British Cardiac Society). 2017; 103(7):529-537. doi:10.1136/heartjnl-2016-309842.

97. **125**. Greenlee, RT, Go, A, Peterson, P, et al. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network. J Am Heart Assoc. 2018. Volume 7, Issue 7.
98. **127.** Ross JS, Bates J, Parzynski CS, et al. Can machine learning complement traditional medical device surveillance? A case study of dual- chamber implantable cardioverter- defibrillators. Medical Devices. 2017; 10:165-188.
99. **128.** Thomas IC, Wang Y, See VY, et al. Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: The National Cardiovascular Data Registry. Heart Rhythm. 2018 Nov 7. pii: S1547-5271(18)31136-6.
100. **132.** Sandhu A, Bao H, Varosy P, et al. Use of Cardiac Resynchronization-Defibrillator Therapy in United States Hospitals: Results from the NCDR ICD Registry. JAMA Cardiol. June 19, 2019.
101. **135A**. Kramer DB, Reynolds MR, Normand SL, et al. Hospice Use Following ICD Implantation in Older Patients: Results from the NCDR. Circulation. 2016 May 24; 133)21): 2030-2037.
102. **135B**. Kramer DB, Reynolds MR, Normand SL, et al. Nursing Home Utilization following Implantable Cardioverter-Defibrillator Implantation in Older Patients: Results from the NCDR. J Am Geriatric Soc. 2017 Feb; 65(2):340-347.
103. **136.** Hakemi EU, Doukky R, Parzynski C, et al. Quadripolar versus Bipolar Leads in CRT: An Analysis from the NCDR ICD Registry. Heart Rhythm. 2019 Jul 29.
104. **137**. Kawata H, Bao H, Curtis JP, et al. Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay Versus Right Bundle Branch Block. Jun 2019, 73 (24) 3082-3099; DOI: 10.1016/j.jacc.2019.04.025
105. **145**. Desai NR, Bourdillon PM, Parzynski CS, et al. Association of the US Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination 2007-2015. JAMA. 2018.
106. **145B.** Bourdillon PM, Parzynsky CS, Minges K, et al. Trends in ICD Implantations and In-Hospital Outcomes after DOJ Investigation. Journal of Cardiac Failure. 2021 Oct 7.
107. **146.** Baskar S, Bao H, Minges K, et al. Characteristics and Outcomes of Pediatric Patients Who Undergo Placement of ICDs - Insights from the NCDR. Circulation EP. 2018 Sep; 11(9): e006542.
108. **149.** Al-Chekakie MO, Bao H, Jones PW, et al. Addition of BP and Weight Transmissions to Standard RM of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circ CQO. May 2017. Vol 10, Issue 5.
109. **150.** Ambrosy A, Friedman D, Hernandez AF, et al. Is Time from Last Hospitalization for Heart Failure to Placement of a Primary Prevention ICD Associated with Patient Outcomes? Circulation. 2018 Dec 11; 138(24):2787-2797.
110. **151.** Friedman DJ, Qin Li, Parzynski C, et al. Longitudinal Outcomes of a Subcutaneous or Transvenous Implantable Cardioverter Defibrillators in Older Patients. JACC. 2022 Mar; 79(11)
111. **158.** Friedman D, Parzynski C, Heist K, et al. Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: A Report from the National Cardiovascular Data Registry. Circ AHA. 2018. Volume 137, Issue 19.
112. **162**. Fudim M, Ali-Ahmed F, Parzynski C, et al. Periprocedural Risk and Survival after ICD Placement in Older Patients with Advanced Heart Failure. JAMA Cardiology. 2020.
113. **167.** Higgins AY, Annapureddy A, Wang Y, et al. Survival Following Implantable Cardioverter-

Defibrillator Implantation in Patients with Amyloid Cardiomyopathy. J Am Heart Assoc. 2020 Sep 15; 9(18): e016038.

114. **170.** Hyman MC, Bao H, Curtis JP, et al. A Comparison of Left Ventricular Lead Upgrade versus Continued Medical Care Among Patients Eligible for CRT at the Time of Defibrillator Generator Replacement: Predictors of Left Ventricular Lead Upgrade and Associations with Long-term Outcomes. Heart Rhythm. 2020 Jun 1: S1547-5271(20)30530-0.
115. **171.** Chui PW, Wang Y, Ranasinghe I, et al. Association of Physician Specialty with Long-Term Implantable Cardioverter-Defibrillator Complication and Reoperations Rates Insights From the NCDR Implantable Cardioverter-Defibrillator Registry. Circulation: Cardiovascular Quality and Outcomes. June 2019. https://doi.org/10.1161/CIRCOUTCOMES.118.005374.
116. **173.** Pun PH, Parzynski CS, Friedman DJ, Sanders G, Curtis JP, Al-Khatib S. Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Dialysis Patients. CJASN. September 24, 2020. doi: 10.2215/CJN.0792052.
117. **176.** Castro-Dominguez YS, Curtis JP, Masoudi FA, et al. Hospital Characteristics and Early Enrollment Trends in the American College of Cardiology Voluntary Public Reporting Program. JAMA Netw Open. 2022;5(2)
118. **184**. Borne R, Masoudi FA, Curtis JP, et al. Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the NationalCardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. JAMA Network Open. 2021.
119. **190.** Madias C, Parzynski CS, Burrows A, et al. Utilization effects of the Affordable Care Act on implantable cardioverter-defibrillator therapy: findings from the NCDR. JACC. 2020.
120. **193.** Tcheugui JE, Masoudi FA, Bao H, et al. Body Mass Index and Outcomes of Cardiac Resynchronization with Implantable Cardioverter Defibrillator Therapy in Older Patients with Heart Failure.
121. **194.** Bates J, Parzynski CS, Dhruva SS, et al. Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators. Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):848-856.
122. **202.** Higgins AY, Bjerre J, Parzynski CS, et al. Mortality and Readmission in Non-Ischemic Compared with Ischemic Cardiomyopathies After ICD Implantation. Am J of Cardiol. 2020 Jul 24: S0002-9149(20)30769-4.
123. **214**. Padala SK, Gunda S, Li S, et al. A risk score model for predicting intraprocedural cardiac injury during implantable cardioverter defibrillator implantation: Insights from the National Cardiovascular Data Registry. J Cardiovasc Electrophysiology. 2019 Feb; 30(2):212-220. Doi:10.1111/jce.13823.
124. **220.** Borne RT, Varosy P, Lan Z, et al. Trends in use of single versus dual chamber ICDs among patients without a pacing indication. JAMA Network Open. March 22, 2022.
125. **226.** Prutkin JM, Wang Y, Escudero CA, et al. Prevalence, Predictors and Adverse Events Associated with Defibrillation Threshold Testing in Pediatric Patients: Results from the NCDR. Int J Cardiol. 2020.
126. **241.** Resnic FS, Majithia A, Dhruva SS, et al. Active Surveillance of the Implantable Cardioverter-Defibrillator Registry for Defibrillator Lead Failures. Circulation: Cardiovascular Quality and Outcomes. April 2020.
127. **248.** Zeitler EP, Wang Y, Pokorney SD, et al. Comparative outcomes of Riata and Fidelis lead management strategies: Results from the NCDR-ICD Registry. PACE. 2021 Aug 13.
128. **N/A.** Hummel JP, Leipold RJ, Amorosi SL, et al. Outcomes and costs of remote patient monitoringamong patients with implanted cardiac defibrillators: An economic model based on the PREDICT

RM database. J Cardiovasc Electrophysiol.2019; 30:1066-1077.https://doi.org/10.1111/jce.13934.

IN PRESS

1.

PUBLISHED

1. **1**. Martin GR, Beekman RH, Ing FF, et al. The IMPACT registry: Improving Pediatric and Adult Congenital Treatments. Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual. 2010; 13(1):20-5.
2. **2.** Vincent RN, Moore J, Beekman III RH, et al. Procedural characteristics and adverse events in diagnostic and interventional catheterizations in pediatric and adult CHD: initial report from the IMPACT Registry. Cardiology in the Young. 2015; 26(1):70-78.
3. **3.** Moore JW, Vincent RN, Beekman RH, et al. Procedural Results and Safety of Common Interventional Procedures in Congenital Heart Disease: Initial Report from the National Cardiovascular Data Registry. JACC. 2014; 64(23):2439-2451.
4. **4.** Holzer R, Beekman R, Benson L, et al. Characteristics and safety of interventions and procedures performed during catherization of patients with congenital heart disease: early report from the national cardiovascular data registry. Cardiology in the Young. 2016; 26(6):1202-12.
5. **5.** Jayaram N, Beekman RH, Benson L, et al. Adjusting for Risk Associated with Pediatric and Congenital Cardiac Catheterization: A Report from the NCDR IMPACT Registry. Circulation. 2015; 132:1863-1870.
6. **8.** Jayaram N, Spertus JA, O' Byrne ML, et al. Relationship between hospital procedure volume and complications following congenital cardiac catheterization: A report from the Improving Pediatric and Adult Congenital Treatment (IMPACT) registry. AHJ. 2017.
7. **9.** Lewis MJ, Kennedy KF, Ginns J, et al. Procedural Success and Adverse Events in Pulmonary Artery Stenting: Insights From the NCDR. JACC. 2016; 67(11):1327-1335.
8. **11.** O'Byrne ML, Gillespie MJ, Kennedy KF, et al. The influence of deficient retro-aortic rim on technical success and early adverse events following device closure of secundum atrial septal defects: An Analysis of the IMPACT Registry®. Catheter Cardiovasc Interv. 2016; 89(1).
9. **13.** Boe BA, Zampi JD, Kennedy KF, et al. Acute Success of Balloon Aortic Valvuloplasty in the Current Era: A NCDR Study. JACC Cardiovasc Interv. 2017; 10(17):1717-1726.
10. **14.** Stefanescu-Schmidt AC, Armstrong A, Kennedy KF, et al. Prediction of adverse events after catheter-based procedures in adolescents and adults with congenital heart disease in the IMPACT registry. Eur Hear J. 2017; 38(26):2070-2077.
11. **16.** O'Byrne M, Huang J, Asztalos I, et al. Pediatric/Congenital Cardiac Catheterization Quality: An Analysis of Existing Metrics. J Am Coll Cardiol Cardiovasc Interv. 2020 Dec, 13 (24) 2853–2864.
12. **18A.** Andrew C Glatz, Kevin F Kennedy, Jonathan J Rome, Michael L O'Byrne. Variations in practice patterns and consistency with published guidelines for balloon aortic and pulmonary valvuloplasty: An analysis of data from the IMPACT® Registry JACC Cardiovasc Interv. 2018 Mar 26; 11(6): 529–538. doi: 10.1016/j.jcin.2018.01.253 PMCID: PMC6156789**.**
13. **18B.** O'Byrne, Kennedy, Rome et al; Variation in practice patterns in device closure of atrial septal defects and patent ductus arteriosus: An analysis of data from the Improving Pediatric and Adult Congenital Treatment (IMPACT) registry. Am Heart J. 2018 Feb; 196:119-130. doi: 10.1016/j.ahj.2017.10.018. Epub 2017 Nov 2.
14. **19.** Jayaram N, Spertus JA, Kennedy KF, et al. Modeling Major Adverse Outcomes of Pediatric and Adult Patients with Congenital Heart Disease Undergoing Cardiac Catheterization: Observations from the NCDR IMPACT Registry. Circulation. 2017 Sep 7; 136(13).
15. **21.** Martin G, Anderson J, Vincent R, et al. IMPACT Registry and National Pediatric Cardiology Quality Improvement Collaborative: Contributions to Quality in Congenital Heart Disease. World Journal for Pediatric and Congenital Heart Surgery. 2019.
16. **23.** Backes C, et al. Transcatheter Occlusion of the Patent Ductus Arteriosus in 747 Infants <6 kg: Insights from the NCDR IMPACT Registry. JACC Cardiovasc Interv. 2017; 10(17):1729-1737.
17. **24.** O'Byrne, M, Kennedy, K, Kanter, J et al. Risk Factors for Major Early Adverse Events Related to Cardiac

Catheterization in Children and Young Adults with Pulmonary Hypertension: An Analysis of Data From the IMPACT (Improving Adult and Congenital Treatment) Registry. Journal of the American Heart Association. 2018.

18. **44.** O'Byrne ML, Kennedy KF, Steven JM, et al. Sedation and Anesthesiologist Care in the Pediatric/Congenital Catheterization Laboratory A Study Utilizing Data from the IMPACT Registry. JACC: CARDIOVASCULAR INTERVENTIONS. 2021.
19. **51.** Janson CM, Shah MJ, Kennedy K, et al. Comparison of Outcomes of Pediatric Catheter Ablation by Anesthesia Strategy: A Report from the NCDR IMPACT Registry. Circulation: Arrhythmia and Electrophysiology. July 2021.
20. **53.** Deshpande SR, Kennedy KF, Vincent RN, et al. Atrial septostomy in patients supported with Ven arterial extracorporeal membrane oxygenation: Analysis of the IMPACT registry data. Int J Artif Organs . 2020.

IN PRESS

PUBLISHED

1. **17**. Varosy P, Masoudi FA, Reisman M, et al. Procedural Safety of Watchman Implantation: The US Nested Post Approval Study. JACC. 2018.
2. **36.** Freeman J, Varosy P, Price M et al. The NCDR Left Atrial Appendage Occlusion Registry. JACC. Vol 75, NO. 13.
3. **46.** Darden D, Duong T, Du C, et al. Sex Differences in Procedural Outcomes with Left Atrial Appendage Occlusion: Insights from the NCDR LAAO Registry. JAMA Cardiology.

IN PRESS

1. **21**. Freeman J, Higgins A, Wang Y, Du C, Friedman DF, Daimee U, Minges KA, Pereira L, Goldsweig AM, Price MJ, Reddy VY, Gibson D, Doshi SK, Varosy PD, Masoudi FA, Curtis JP. Antithrombotic Therapy after Left Atrial Appendage Occlusion in Patients with Atrial Fibrillation. J Am Coll Cardiol. In press.
2. **32.** Alkhouli M, Du C, Killu A, Simard T, Noseworthy PA, Killu A, Friedman PA, Curtis JP, Freeman JV, Holmes DR. Clinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion: Insights from the NCDR LAAO Registry. JACC CE. In press.
3. **58.** Friedman D, Du C, Wang Y, Agarwal V, Varosy P, Masoudi FA, Holmes Jr, D, Reddy V, Price M, Curtis JP, Freeman JV. Patient Level Analysis of Watchman LAAO in Practice Versus Clinical Trials. JACC Intervent. In press.

PINNACLE Registry®

PUBLISHED

1. **1.** Smolderen KG, Sperus JA, Tang F, et al. Treatment Differences by Health Insurance Among Outpatients with Coronary Atery Disease: Insights from the NCDR. Journal of the American College of Cardiology. 2013 March 12; 61(10):1069-75.
2. **2.** Chan PS, Maddox TM, Tang F et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE Program). American Journal of Cardiology. 2011; 108:1136–1140.
3. **3.** Goldsweig AM, Reid KJ, Gosch K, et al. Contemporary Use of Dual Anti-platelet Therapy for Preventing Cardiovascular Events. Am J Manag Care. 2014;20(8):659-665.
4. **4.** Spinler SA, Cziraky MH, Tang F et al. Patient Eligibility for Medication Therapy Management Services Within Practices Enrolled in the PINNACLE Registry™. American Health & Drug Benefits. 2013; 6(7):367-374.
5. **5.** Spinler SA, Cziraky MJ, Willey VJ, et al. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry). Am J Cardiol. 2015; 116:547-553.
6. **6.** Arnold SV, Spertus JA, Tang F et al. Statin use in outpatients with obstructive coronary artery disease. Circulation. 2011; 124:2405-2410.
7. **7.** Oetgen WJ, Mullen JB, Mirro MM, et al. Cardiologists, the PINNACLE Registry, and the "Meaningful Use" of Electronic Health Records. Journal of the American College of Cardiology. 2011; 57:1560-1563.
8. **8.** May DC, Fiocchi FF, Kehoe K et al. Improving Cardio Care in the Outpatient Setting: Implementing the PINNACLE Registry in a single-specialty practice. Physician Executive Journal. 2011; 37:38-42.
9. **9A.** Dehmer GJ, Drozda JP Jr, Brindis RG, et al. Public reporting of clinical quality data: an update for cardiovascular specialists. J Am Coll Cardiol. 2014 Apr 8.
10. **9B.** Chan P, Oetgen W, Spertus J, et al. The Improving Continuous Cardiac Care (IC3) Program and Outpatient Quality Improvement. The American Journal of Medicine. 2010; 123(3): 217- 219.
11. **9C.** Chan PS, Oetgen WJ, Buchanan D, et al. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation and Clinical Excellence) program. J Am Coll Cardiol. 2010.
12. **10.** Erb BD, Allen JM, Chambers L, et al. The PINNACLE Network: Facilitating Quality of Care in Outpatient Cardiovascular Medicine. US Cardiology. 2011; 8(1):12–5.
13. **11.** Gupta D, Tang F, Masoudi FA, et. Al. Practitioner Gender and Quality of Care in Ambulatory Cardiology Practices: A Report from the NCDR PINNACLE Registry. J Cardiovasc Nurs. 2017.
14. **12.** Peterson PN, Chan PS, Spertus JA, et al. Practice-level Variation in use of Recommended Medications among Outpatients with Heart Failure: Insights from the NCDR PINNACLE Registry. Circ Heart Fail. 2013 Nov; 6(6):1132-8.
15. **13.** Maddox TM, Chan PS, Spertus JA, et al. Variation in CAD Secondary Prevention Prescription among Outpatient Cardiology Practices: Insights from the NCDR®. JACC. 2014: 63(6); 539-546.
16. **14.** Marzec LN, Wang J, Shah ND, et al. Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2017 May 23; 69(20):2475-2484.

17. **15.** Oetgen WJ, et al. Duelin' Registries. Circulation: Cardiovascular Quality and Outcomes. 2011; 4;483-485.
18. **16.** Oetgen WJ, Mullen JB, Mirro MM, et al. Electronic Health Records, the PINNACLE Registry, and Quality Care. Archives of Internal Medicine. 2011; 171(10):953-954.
19. **17.** Subherwal S, Patel MR, Tang F, et al. Socioeconomic Disparities in Use of Cardioprotective Medications Among Patients with Peripheral Artery Disease—An Analysis of the American College of Cardiology's NCDR PINNACLE Registry®. JACC. 2013; (62) 1:51-57.
20. **18.** Frederick MA, Singh T, Salami S, et al. First Steps: Exploring Use of a Prospective, Office-Based Registry as a Foundation for Quality Improvement in Cardiology Training. Journal of Graduate Medical Education. 2013; 5(4): 694-699.
21. **23.** Maddox TM, Chan PS, Spertus JA, et al. Variation in CAD Secondary Prevention Prescription among Outpatient Cardiology Practices: Insights from the NCDR®. JACC. 2014:63(6);539-546.
22. **24.** Glusenkamp NT, Oetgen WJ, Mullen B, et al. The Million Hearts Initiative-Targeting Key Drivers of Cardiovascular Mortality from a Medical Specialty Society Perspective. US Cardiology. 2012;9(1):66–70.
23. **25.** Hsu JC, Chan PS, Tang F, et al. Differences in Anticoagulant Therapy Prescription in Patients with Paroxysmal Versus Persistent Atrial Fibrillation: Insights from the NCDR® PINNACLE Registry. Am J Med. 2015; 128 (6): 654.e1-654.e10.
24. **26.** Hsu JC, Chan PS, Tang F, et al. Oral Anticoagulant Prescription in Atrial Fibrillation Patients with a Low Risk of Thromboembolism: Insights from the NCDR® PINNACLE Registry. JAMA Intern Med. 2015; 175(6):1062-1065.
25. **27.** Bandeali SJ, Gosch K, Alam M, et al. Coronary Artery Disease Performance Measures and Statin Use in Patients with Recent Percutaneous Coronary Intervention or Recent Coronary Artery Bypass Grafting (From the NCDR® PINNACLE Registry). Am J Cardiol. 2015; 115 (8): 1013-1018.
26. **28.** Fleming LM, Jones P, Chan PS, et al. Relationship of Provider and Practice Volume to Performance Measure Adherence for Coronary Artery Disease, Heart Failure, and Atrial Fibrillation: Results from the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2016. Jan;9(1):48-54.
27. **31.** Virani SS, Maddox TM, Chan PS, et al. Provider Type and Quality of Outpatient Cardiovascular Disease Care, Implications for the Affordable Care Act: Insights from the NCDR®PINNACLE Registry. Journal of the American College of Cardiology. 2015; 66(16):1803-1812. doi: 10.1016/j.jacc.2015.08.017.
28. **32.** Eapen ZJ, Tang F, Jones PG, et al. Variation in performance measure criteria significantly affects cardiology practice rankings: Insights from the National Cardiovascular Data Registry's Practice Innovation and Clinical Excellence Registry. Am Heart J. 2015 Jun; 169 (6): 847-853.
29. **33.** Hira RS, Kennedy K, Nambi V, et al. Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease: Insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry. J Am Coll Cardiol. 2015; 65(2): 111-121.
30. **34.** Hira RS, Kennedy K, Jneid H, et al. Frequency and Practice-Level Variation in Inappropriate and Nonrecommended Prasugrel Prescribing: Insights from the NCDR PINNACLE Registry. JACC. 2014: 63(25_PA): 2876-7.
31. **35.** Hess PL, Gosch KL, Jani SM, et al. Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry. Am Heart J. 2021 Oct.
32. **37.** Hsu JC, Maddox TM, Kennedy K, Katz DF, Marzec LN, Lubitz SA, Gehi AK, Turakhia MP, Marcus GM. Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. J Am

Coll Cardiol.

33. **38.** Hsu JC, Maddox TM, Kennedy K, et al; Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke; 2016-6-28; 67; 25.
34. **50.** Karney K, Thande N, Gosch K, et al. Relationship Between Provider Experience and Cardiac Performance Measures in Outpatients (from the NCDR). AJC. 2019.
35. **60.** Wasfy JH, Kennedy KF, Chen JS, et al. Practice Variation in Triple Therapy for Patients with Both Atrial Fibrillation and Coronary Artery Disease: Insights from the ACC's National Cardiovascular Data Registry. JACC: EP. 2016.
36. **61.** Khalid U, Bandeali S, Jones P, et al. Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention with Stent Implantation (from the NCDR PINNACLE Registry). American Journal of Cardiology. 2019. Volume 124, Issue 12, 1807 – 1812.
37. **64.** Maddox TM, Borden WB, Tang F, et al. Implications of the 2013 ACC/AHA Cholesterol Guidelines for Adults in Contemporary Cardiovascular Practice: Insights from the NCDR PINNACLE Registry. J Am Coll Cardiol. 2014; 64(21): 2183-2192. doi: 10.1016/j.jacc.2014.08.041.
38. **65.** Borden WB, Maddox TM, Tang F, et al. Impact of the 2014 Expert Panel Recommendations for Management of High Blood Pressure on Contemporary Cardiovascular Practice: Insights from the National Cardiovascular Data Registry PINNACLE Registry. J Am Coll Cardiol. 2014; 64(21): 2196-2203. doi: 10.1016/j.jacc.2014.09.022.
39. **71.** Gehi AK, Doros G, Glorioso TJ, et al. Factors associated with rhythm control treatment decisions in patients with atrial fibrillation-Insights from the NCDR PINNACLE registry. Am Heart J. 2017 May; 187:88-97.
40. **72.** Katz DF, Maddox TM, Turakhia M, et al. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment Analysis from the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. Circulation: Cardiovascular Quality and Outcomes. 2017; 10: e003476.
41. **73.** Contreras JP, Hong KN, Castillo J, et al. Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. Clinical cardiology.
42. **74.** Virani S, Maddox T, Khalid MU, et al. Treatment of AF in American Indians and Alaska Natives Insights from the NCDR PINNACLE-AF Registry. JACC. 2020.
43. **75.** Thompson LE, Maddox TM, Lei L, et al. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report from the NCDR PINNACLE Registry. JAHA. 2017.
44. **76**. Lubitz SA, Khurshid S, Lu-Chen W, et al. Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. AHJ. 2018.
45. **77.** Yong, C, Liu Y, Apruzzese P, et al. Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the ACC NCDR PINNACLE Registry. AHJ. 2018.
46. **83.** Wong J, Maddox T, Kennedy K, et al. Comparing Major Bleeding Risk in Outpatients with Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry). Am J Cardiol. 2020 May 15; 125(10):1500-1507. doi: 10.1016/j.amjcard.2020.02.028.
47. **86.** Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017 Apr 1; 2(4):361-369.

48. **87.** Pokharel Y, Gosch K, Nambi V, et al. Frequency and Practice Level Variation in Statin Use Among Patients with Diabetes: Insights from the ACC NCDR® PINNACLE Registry. Journal of the American College of Cardiology. 2016;68(12):1368-1369. doi: 10.1016/j.jacc.2016.06.048.
49. **90.** Maddox TM, Tang F, Downs JR, et al. Applicability of the IMPROVE-IT Trial to Current Patients with Acute Coronary Syndrome: An NCDR Research to Practice Project. JAMA Internal Medicine. 2017; 177(6):887-889. doi:10.1001/jamainternmed.2017.0754.
50. **92.** Larry A, Fengming T, Jones P, et al. Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: Insights from the NCDR PINNACLE® registry. BMC Cardiovascular Disorders. 2018. 10.1186/s12872-018-0808-2.
51. **93**. Hess P, Kennedy K, Cowherd MM, et al. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018. Volume 195:151-152. doi: 10.1016/j.ahj.2017.09.004.
52. **94.** Mathew JS, Marzec LN, Kennedy KF, et al. Atrial Fibrillation in Heart Failure US Ambulatory Cardiology Practices, and the Potential for Uptake of Catheter Ablation: An NCDR Research to Practice (R2P) Project. J Am Heart Assoc. 2017.
53. **95.** Thompson L, Kennedy K, Maddox TM, et al. MANAGEMENT OF RESISTANT HYPERTENSION AND IMPLICATIONS OF PATHWAY-2 TRIAL IN US CARDIOLOGY PRACTICE: INSIGHTS FROM THE NCDR PINNACLE REGISTRY. J Am Coll Cardiol. 2018 Mar.
54. **100.** Tanguturi VK, Kennedy KF, Virani SS, et al. Association between poverty and appropriate statin prescription for the treatment of hyperlipidemia in the United States: An analysis from the ACC NCDR PINNACLE registry. Cardiovasc Revasc Med. 2019 Dec 27. pii: S1553-8389(19)30827-9. doi: 10.1016/j.carrev.2019.12.026.
55. **103.** Sardana M, Tang Y, Magnani JW, et al. Provider-Level Variation in Smoking Cessation Assistance Provided in the Cardiology Clinics: Insights from the NCDR PINNACLE Registry. J Am Heart Assoc. 2019 Jul 2; 8(13): e011412. doi: 10.1161/JAHA.118.011307.
56. **130.** Bradley SM, Hess GP, Stewart P, et al. Implications of the PEGASUS-TIMI 54 trial for US clinical practice. Open Heart. 2017; 4(1): e000580. doi:10.1136/openhrt-2016-000580.
57. **146.** Blumenthal DM, Maddox TM, Aragam K, et al. Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease. Circ: CQO. 2021.
58. **156.** Figueroa JF, Blumenthal DM, Feyman Y, et al. Differences in Management of Coronary Artery Disease in Patients with Medicare Advantage vs Traditional Fee-for-Service Medicare Among Cardiology Practices. JAMA Cardiol. 2019 Feb 20. [Epub] PMID: 30785590.
59. **158.** Sciria CT, Maddox TM, Marzec L, et al. Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry. Clinical Cardiology. 2020.
60. **169.** Wadhera RK, Bhatt DL, Kin AJH, et al. Association of Outpatient Practice-Level Socioeconomic Disadvantage with Quality of Care and Outcomes Among Older Adults with Coronary Artery Disease Implications for Value-Based Payment. Circ: Cardiovasc Qual Outcomes. 2020;13: e005977. DOI: 10.1161/CIRCOUTCOMES.119.005977.
61. **176.** Gu K, Mahtta D, Kaneria A, et al. Racial disparities among Asian Americans with atrial fibrillation: An analysis from the NCDR® PINNACLE Registry. 2021. International Journal of Cardiology. 329 (2021) 209-216.
62. **177.** Virani S, et al. Frequency and Practice-Level Variation in Lipid Lowering Medication Use Among

Patients with Very High LDL-C Levels: Insights from the NCDR®PINNACLE Registry.

63. **181.** Ibrahim NE, Song Y, Cannon CP, et al. Alteration of medical therapy in patients with heart failure relative to change in symptom severity. EESC Heart Failure. 2019; 6: 1085–1087.
64. **182.** Ibrahim NE, Song Y, Cannon CP, et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC Heart Fail. 2019 Aug;6(4):784-792. doi: 10.1002/ehf2.12455. 2019.
65. **205.** Hsu JC, Reynolds MR, Song Y, et al. Outpatient Prescription Practices in Patients with Atrial Fibrillation (From the NCDR PINNACLE Registry). AJC. 2021.
66. **207.** Hira RS, Gosch KL, Kazi DS, et al. Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights from the NCDR PINNACLE Registry. Circ: Cardiovasc Qual Outcomes. 2022 Jan 31.
67. **219.** Maddox TM, Song Y, Allen J, et al. Trend in U.S. Ambulatory Cardiovascular Care 2013 to 2017. JACC. 2020.

IN PRESS

1. Borden W, et al. Reducing Cardiovascular Risk in the Medicare Million Hearts Risk Reduction Model. In Press.

PVI Registry

PUBLISHED

1. **9**. Bhardwaj B, Spertus JA, Kennedy KF, et al. Bleeding Complications in Lower-Extremity Peripheral Vascular Interventions: Insights from the NCDR PVI Registry. JACC: CI. 2019.
2. **10**. Jones WS, Kennedy KF, Hawkins BM, et al. Expanding Opportunities to Understand Quality and Outcomes of Peripheral Vascular Interventions: The ACC NCDR PVI Registry. AHJ. 2019.
3. **13**. Goldsweig AM, Kennedy KF, Abbott JD, et al. Patient Radiation Dosage During Lower Extremity Endovascular Intervention. JACC CI. March 2019.
4. **19**. Rymer J, Kennedy K, Lowenstern A, et al. IN-HOSPITAL OUTCOMES AND DISCHARGE MEDICATION USE AMONG PATIENTS PRESENTING WITH CRITICAL LIMB ISCHEMIA VERSUS CLAUDICATION: INSIGHTS FROM THE NCDR PVI REGISTRY. J Am Coll Cardiol. 2019 Mar, 73 (9 Supplement 1) 2036.
5. **20.** Safley DM, Salisbury AC, Tsai TT, et al. Acute Kidney Injury Following In-Patient Lower Extremity Vascular Intervention: From the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2021 Feb.
6. **21.** Salisbury AC, Safley DM, Kennedy KF, et al. Development and validation of a predictive model for bleeding after peripheral vascular intervention: A report from the National Cardiovascular Data Registry Peripheral Vascular Interventions Registry. Catheter Cardiovasc Interv. 2021 Dec 1.
7. **34.** Krawisz AK, Rosenfield K, White CJ, et al. Clinical Impact of Contralateral Carotid Occlusion in Patients Undergoing Carotid Artery Revascularization. JACC. 2021.
8. **36**. Weissler EH, Annapureddy A, Wang Y, et al. Paclitaxel-Coated Devices in the Treatment of Femoropopliteal Stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. AHJ. 2020 Dec.

IN PRESS

1. . Weissler EH, Wang Y, Gales JM, et al. Cardiovascular and limb events following endovascular revascularization among patients ≥65 years old: An ACC PVI Registry Analysis. JAHA. In press.

TVT Registry

PUBLISHED

1. **1.** Carroll JD, Edwards FH, Marinac-Dabic D, et al. The STS-ACC Transcatheter Valve Therapy National Registry: A New Partnership and Infrastructure for the Introduction and Surveillance of Medical Devices and Therapies. JACC. 2013.
2. **2.** Mack MJ, Brennan JM, Brindis R, et al. Outcomes following transcatheter aortic valve replacement in the United States. JAMA. 2013 Nov 20;310(19):2069-77.
3. **3.** Brennan JM, Holmes DR, Sherwood MW, et al. The association of transcatheter aortic valve replacement availability and hospital aortic valve replacement volume and mortality in the United States. Ann Thorac Surg. 2014 Dec;98(6):2016-22.
4. **5.** O'Brien SM, Cohen DJ, Rumsfeld JS, et al. Variation in Hospital Risk-Adjusted Mortality Rates Following Transcatheter Aortic Valve Replacement in the United States: A Report from the STS/ACC TVT Registry. Circ Cardiovasc Qual Outcomes. 2016; 9:560-565.
5. **7.** Sherwood MW, Vemulapalli S, Harrison JK, et al. Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry. AHJ. 2018.
6. **8.** Holmes DR, Brennan JM, Rumsfeld JS, et al. Clinical Outcomes at 1 Year Following Transcatheter Aortic Valve Replacement. JAMA. 2015; 313(10):1019-1028. doi:10.1001/jama.2015.1474.
7. **27.** Alfredsson J, Stebbins A. Brennan JM, et al. Gait Speed Predicts 30-Day Mortality After Transcatheter Aortic Valve Replacement: Results from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Circulation. 2016.
8. **33.** Arnold SV, Spertus JA, Vemulapalli S, et al. Association of Patient-Reported Health Status with Long-Term Mortality After Transcatheter Aortic Valve Replacement Report From the STS/ACC TVT Registry. Circ Cardiovasc Interv. 2015.
9. **34.** Hira RS, Vemulapalli S, Li Z, et al. Trends and Outcomes of Off-label Use of Transcatheter Aortic Valve Replacement Insights from the NCDR STS/ACC TVT Registry. JAMA Cardiol. 2017;2(8):846-854.
10. **37.** Baron SJ, Arnold SV, Herrmann HC, et al. Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2016;67(20):2349-2358. doi: 10.1016/j.jacc.2016.03.514.
11. **42.** Mavromatis K, Thourani VH, Stebbins A, et al. Transcatheter Aortic Valve Replacement in Patients with Aortic Stenosis and Mitral Regurgitation. Ann Thorac Surg. 2017. Volume 104, Issue 6.
12. **44.** Thourani VH, Jensen HA, Babaliaros V, et al. Transapical and Transaortic Transcatheter Aortic Valve Replacement in the United States. Ann Thorac Surg 2015; 100:1718–27.
13. **57.** Szerlip M, Zajarias A, Vemalapalli S, et al. Transcatheter Aortic Valve Replacement in Patients with End-Stage Renal Disease. JACC 2019.
14. **58.** Tuzcu EM, Kapadia SR, Vemulapalli S, et al. Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses; The STS/ACC Registry. JACC. 2018.
15. **72.** Arsalan M, Szerlip M, Vemilapalli S, et al. Should Transcatheter Aortic Valve Replacement Be Performed in Nonagenarians? Insights From the STS/ACC TVT Registry. JACC. 2016; 67 (10).
16. **74.** Suri RM, Gulack BC, Brennan JM, et al. Outcomes of Patients with Severe Chronic Lung Disease Who Are Undergoing Transcatheter Aortic Valve Replacement. The Annals of Thoracic Surgery. 29 August 2015.
17. **90.** Chandrasekhar J, Dangas G, Yu J, et al. Sex-Based Differences in Outcomes with Transcatheter Aortic Valve Therapy. JACC. 12/2016; Vol 68 No. 25; Pages 2733-44.
18. **101.** Halim S, Edwards FH, Dai D, et al. Outcomes of Transcatheter Aortic Valve Replacement in Patients with Bicuspid Aortic Valve Disease A Report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Circulation. 26 Feb 2020. https://doi.org/10.1161/CIRCULATIONAHA.119.040333.

19. **105.** Fadahunsi, Olowoyeye A, et al. Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement: Analysis from STS/ACC TVT Registry. JACC: Cardiovascular Interventions. November 14, 2016. 9 (21) 2189-2199.
20. **106.** Carroll JD, Vemulapalli S, Dai D, et al. Procedural Experience for Transcatheter Aortic Valve Replacement and Relation to Outcomes. JACC. July 2017, Volume 70, Issue 1.
21. **107.** Holmes DR, Nishimura RA, Grover FL, et al. Annual Outcomes with Transcatheter Valve Therapy: From the STS/ACC TVT Registry. J Am Coll Cardiol. 2015; ISSN 0735-1097.
22. **108.** Edwards FH, Cohen DJ, O'Brien SM, et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality After Transcatheter Aortic Valve Replacement. JAMA Cardiol. March 09, 2016. doi:10.1001/jamacardio.2015.0326.
23. **109.** Sorajja P, Mack M, Vemulapalli S, et al. Initial Experience with Commercial Transcatheter Mitral Valve Repair in the United States. JACC. 2016; 67 (10).
24. **110.** Sherwood MW, Xiang K, Matsouaka R, et al. Incidence, Temporal Trends, and Associated Outcomes of Vascular and Bleeding Complications in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement Insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. Circulation: Cardiovascular Interventions. 15 Jan 2020. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008227.
25. **119.** Hyman MC, Vemulapalli S, Szeto WY, et al. Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Insights from the NDCR STS/ACC TVT Registry. Circ. November 2017.
26. **130.** Dodson JA, Williams MR, Cohen DJ, et al. Home Practice of Direct-Home Discharge and 30-Day Readmission After Transcatheter Aortic Valve Replacement in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry. JAHA. August 2017.
27. **133.** Vemulapalli S, Dai D, Hammill BG, et al. Hospital Resource Utilization Before and After Transcatheter Aortic Valve Replacement: The STS/ACC TVT Registry. JACC. 2019.
28. **140.** McCarthy FH, Vemulapalli S, Zhuokai L, et al. The Association of Tricuspid Regurgitation with Transcatheter Aortic Valve Replacement Outcomes: A Report from The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. ATS. March 2018.
29. **153.** Joseph L, Bashir M, Xiang Q, et al. Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement: Findings from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. JACC: CI. April 2018.
30. **155.** Vora AN, Dai D, Matsuoka R, et al. Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis from the STS/ACC TVT Registry. JACC: CI. 2018.
31. **156.** Pineda AM, Harrison JK, Kleiman N, et al. Incidence and Outcomes of Surgical Bailout during TAVR: Insights from the STS/ACC TVT Registry. JACC CI. 2019.
32. **161.** Sharma A, Lavie CJ, Elmariah S, et al. Relationship of Body Mass Index with Outcomes After Transcatheter Aortic Valve Replacement: Results from the National Cardiovascular Data-STS/ACC TVT Registry. Mayo Clin Proc. 2020.
33. **169.** Arnold SV, Spertus JA, Vemulapalli S, et al. Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population: A Report from the STS/ACC TVT Registry. JAMA Cardiol. 2017. doi:10.1001/jamacardio.2016.5302.
34. **174.** Abramowitz Y, Vemulapalli S, Chakravarty T, et al. Clinical Impact of Diabetes Mellitus on Outcomes After Transcatheter Aortic Valve Replacement: Insights from the STS/ACCC TVT Registry. Circ: CI. November 2017.
35. **176.** Arnold SV, Manandhar P, Vemulapalli S, et al. Patient-Reported Versus Physician-Estimated Symptoms Before and After TAVR. Eur Heart J Qual Care Clin Outcomes. 2021.
36. **180.** Hansen JW, Foy A, Yadav P, et al. Death and Dialysis After Transcatheter Aortic Valve Replacement. An Analysis of the STS/ACC TVT Registry. JACC CI. Sept. 2017.

37. **186.** Wang A, Li Z, Rymer JA, et al. Relation of Post discharge Care Fragmentation and Outcomes in Transcatheter Aortic Valve Implantation from the STS/ACC TVT Registry. AJC. 2019.
38. **190.** Fanaroff AC, Manandhar P, Holmes DR, et al. Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes. Cardiovascular Interventions. 2017; 10: e005456.
39. **191.** Kochar A, Li Z, Harrison JK, et al. Stroke and Cardiovascular Outcomes in Patients with Carotid Disease Undergoing Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv. 2018.
40. **194.** Rymer JA, Xiang Q, Wang A, et al. Factors Associated with and Outcomes of Aborted Procedures During Elective Transcatheter Aortic Valve Replacement. JACC CI. 2019.
41. **197.** Wayangankar SA, Elgendy IY, Xiang Q, et al. Length of Stay After Transfemoral Transcatheter Aortic Valve Replacement an Analysis of the Society of Thoracic Surgeons/ American College of Cardiology Transcatheter Valve Therapy Registry. JACC CI. 2019.
42. **199.** Grover FL, Vemulapalli S, Carroll JD, et al. 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol. 2017; 69:1215-1230.
43. **209.** Masha L, Vemulapalli S, Manandhar P, et al. Demographics, Procedural Characteristics, and Clinical Outcomes When Cardiogenic Shock Precedes TAVR in the United States. JACC: CARDIOVASCULAR INTERVENTIONS VOL. 13, NO. 11, 2020 Clinical Outcomes When Cardiogenic Shock Precedes TAVR in the U.S. JUNE 8, 2020: 1314 – 2 5.
44. **211.** Chhatriwalla Ak, Vemulapalli S, Holmes DR, et al. Institutional Experience with Transcatheter Mitral Valve Repair and Clinical Outcomes. JACC CI. 2019.
45. **215.** Arora SA., Vemulapalli S, Stebbins A, et al. The Prevalence and Impact of Atrial Fibrillation on 1-Year Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair: Results from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. JACC CI. 2019.
46. **224.** Inohara T, Manandhar P, Kosinski AS, et al. Association of Renin-Angiotensin Inhibitor Treatment with Mortality and Heart Failure Readmission in Patients with Transcatheter Aortic Valve Replacement. JAMA. 2018.
47. **236.** Thourani V, Kelly J, et al. Cervantes DG, et al. Transcatheter Aortic Valve Replacement After Prior Mitral Valve Surgery: Results from the Transcatheter Valve Therapy Registry. The Annals of Thoracic Surgery. Volume 109, Issue 6, 1789 - 1796.
48. **240.** Baron SJ, Magnuson EA, Lu M, et al. Health Status After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis. JACC. 2019.
49. **243.** Sorajja P, Kodali S, Reardon MJ, et al. Outcomes for the Commercial Use of Self-Expanding Prostheses in Transcatheter Aortic Valve Replacement: A Report From the STS/ACC TVT Registry. JACC: Cardiovascular Intervention. 2017; 10(20): 2090-2098.
50. **244.** Qintar M, Li Z, Vemulapalli S, et al. Association of Smoking Status with Long-Term Mortality and Health Status After Transcatheter Aortic Valve Replacement: Insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. JAHA. 2019.
51. **245.** Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Registry Report. JACC. 2017.
52. **249.** Shah B, Villablanca P, Vemulapalli S, et al. Outcomes After Transcatheter Mitral Valve Repair in Patients with Renal Disease Insights from the Society of Thoracic Surgeons/American College of Cardiology National Cardiovascular Data Registry Transcatheter Valve Therapy Registry. Circ CI 2019.
53. **253.** Bhardwaj B, Cohen DJ, Vemulapalli S, et al. Outcomes of transcatheter aortic valve replacement for patients with severe aortic stenosis and concomitant aortic insufficiency: Insights from the TVT Registry. AHJ. 2020.
54. **254.** Kolte D, Khera S, Vemulapalli S, et al. Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement: Insights from the STS/ACC TVT Registry. JACC. March 2018.
55. **256.** Guerrero M, Vemulapalli S, Xiang Q, et al. Thirty-Day Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Valve-in-Valve), Failed Surgical Rings (Valve-in-Ring), and Native Valve with Severe Mitral Annular Calcification (Valve-in-Mitral Annular Calcification) in the

United States Data from the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry. Circulation: Cardiovascular Interventions. 6 Mar 2020. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008425.

56. **258.** Rymer JA, Li Z, Cox ML, et al. Pre- Versus Post-Procedure Health Care Resource Utilization in Patients Undergoing Commercial Transcatheter Mitral Valve Repair. J Am Coll Cardiol Intv. 2019 Dec, 12 (23) 2416-2426.
57. **263.** Huded CP, Tuzcu EM, Kishnaswamy A, et al. Association Between Transcatheter Aortic Valve Replacement and Early Postprocedural Stroke. JAMA Card. 2019.
58. **264.** Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis–Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. JACC. 2018.
59. **267.** Kiani S, Stebbins A, Thourani VH, et al. The Effect and Relationship of Frailty Indices on Survival After Transcatheter Aortic Valve Replacement. JACC: CARDIOVASCULAR INTERVENTIONS. 2020.
60. **268.** Thourani VH, O'Brien SM, Kelly JJ, et al. Development and Application of Risk Prediction Model for In-Hospital Stroke after Transcatheter Aortic Valve Replacement: A Report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac Surg. 2019.
61. **269.** Brennan MJ, Thomas L, Cohen DJ, et al. Transcatheter Versus Surgical Aortic Valve Replacement. JACC. July 2017, Volume 70, Issue 4.
62. **270.** Arnold SV, O'Brien SM, Vemulapalli S, et al. Inclusion of Functional Status Measures in the Risk Adjustment of 30-Day Mortality After Transcatheter Aortic Valve Replacement. JACC CI. 2018.
63. **272.** Arnold SV, Li Z, Vemulapalli S, et al. Association of Transcatheter Mitral Valve Repair with Quality-of-Life Outcomes at 30 days and 1 year: Analysis of the Transcatheter Valve Therapy Registry. JAMA Card. 2018.
64. **291.** Alkhouli, M, Holmes DR, Carroll, JD et al. Racial Disparities in the Utilization and Outcomes of TAVR: TVT Registry Report. JACC CI. 2019.
65. **296.** Al-Bawardy R, Vemulapalli S, Thourani VH, et al. Association of Pulmonary Hypertension with Clinical Outcomes of Transcatheter Mitral Valve Repair. JAMA Cardiol. 2020;5(1):47–56. doi:10.1001/jamacardio.2019.4428.
66. **301.** Varshney, AS, Manandhar, P, Vemulapalli, S, et al. Left Ventricular Hypertrophy Does Not Affect 1-Year Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC CI. 2019.
67. **332.** Sanchez CE, Hermiller JB, Pinto DS, et al. Predictors and risk calculator of early unplanned hospital readmission following contemporary self-expanding transcatheter aortic valve replacement from the STS/ACC TVT-registry. Cardiovascular Revascularization Medicine. 2019.
68. **333.** Chandrasekhar J, Vogel B, Baber U, et al. TCT-398 Associations Between Atrial Fibrillation and Clinical Outcomes Among Patients Undergoing Transcatheter Aortic Valve Replacement with Self-Expanding Devices: Results from the United States STS/ACC TVT Registry. Journal of the American College of Cardiology. 2017. DOI: 10.1016/j.jacc.2017.09.496.
69. **334.** Anwaruddin S, Desai N, Szeto W, et al. Self-Expanding Valve System for Treatment of Native Aortic Regurgitation by Transcatheter Aortic Valve Implantation (from the STS/ACC TVT Registry). AJC. 2019.
70. **350.** Arora S, Li Z, Vemulapalli S, et al. Association of Body Mass Index and Outcomes After Transcatheter Mitral Valve Repair. J Am Coll Cardiol. 2020 Mar, 75 (11_Supplement_1) 1188.
71. **353.** Villablanca PA, Vemulapalli S, Stebbins A, et al. Sex-Based Differences in Outcomes with Percutaneous Transcatheter Repair of Mitral Regurgitation with the MitraClip System: Transcatheter Valve Therapy Registry From 2011 to 2017. Circ:CI. 2021.
72. **357.** Marquis-Gravel G, Stebbins A, Kosinski A, et al. Geographic Access to Transcatheter Aortic Valve Replacement Centers in the United States Insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. JAMA Cardiol. 2020; 5(9):1006-1010. doi:10.1001/jamacardio.2020.1725.
73. **371.** Chhatriwalla AK, Vemulapalli S, Szerlip M, et al. Operator Experience and Outcomes of Transcatheter Mitral Valve Repair in the United States. JACC CI. December 2019.

74. **374.** Anwaruddin S, Desai N, Vemulapalli S, et al. Out-of-Hospital 30-Day Mortality After Transfemoral Transcatheter Aortic Valve Replacement: An STS/ACC TVT Analysis. JACC: Cardiovascular Interventions Evaluating. 2021.
75. **399.** Arnold S, Manandhar P, Vemulapalli S, et al. Impact of short-term complications of transcatheter aortic valve replacement on longer-term outcomes: results from the STS/ACC Transcatheter Valve Therapy Registry. European Heart Journal - Quality of Care and Clinical Outcomes. 2019.
76. **406.** Vemulapalli S, Holmes DR Jr, Dai D, et al. Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: A report from the STS/ACC TVT Registry. Am Heart J. 2018 Jan.
77. **409.** Valle JA, Li Z, Kosinski AS, et al. Dissemination of Transcatheter Aortic Valve Replacement in the United States. JACC. 2021 Aug 24.
78. **413.** Butala NM, Chung M, Secemsky EA, et al. Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Variation in Practice and Outcomes. JACC Cardiovasc Interv. 2020;13(11):1277-1287. doi: 10.1016/j.jcin.2020.03.008.
79. **421.** Malik AO, Chhatriwalla AK, Saxon J, et al. Site-Level Variability in 30-Day Patient Outcomes After Transcatheter Mitral Valve Repair in the United States. Circ CQO. 2020.
80. **422.** Hejjaji V, Cohen DJ, Carroll JD, et al. Practical Application of Patient-Reported Health Status Measures for Transcatheter Valve Therapies Insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. Circ: CO. 2021.
81. **438**. Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Nov, 76 (21) 2492–2516
82. **439.** Vemulapalli, S, Carroll, JD, Mack, MJ, et al. Procedural Volume and Outcomes for Transcatheter Aortic-Valve Replacement. NEJM. 2019.
83. **440.** Julien HM, Stebbins A, Vemulapalli S, et al. Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement Insights from the Society of Thoracic Surgeons/American College of Cardiology National Cardiovascular Data Registry–Transcatheter Valve Therapy Registry. Circ. 2021.
84. **449.** Russo MJ, McCabe JM, Thourani VH, et al. Case Volume and Outcomes after TAVR with Balloon-Expandable Protheses: Insights from the TVT Registry. JACC. 2019.
85. **453.** Dahle TG, Kaneko T, McCabe JM, et al. Outcomes Following Subclavian and Axillary Artery Access for Transcatheter Aortic Valve Replacement: STS/ACC TVT Registry Report. JACC CI. 2019.
86. **454.** Makkar RR, Yoon SH, Leon MB, et al. Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke. JAMA. 2019 Jun 11;321(22):2193-2202.
87. **455.** Desai ND, O'Brien S, Cohen DJ, et al. A Composite Metric for Benchmarking Site Performance in TAVR: Results from the STS/ACC TVT Registry. 2021. https://doi.org/10.1161/CIRCULATIONAHA.120.051456.
88. **456.** Tang GHL, Sengupta A, Alexis SL, et al. Outcomes of Prosthesis-Patient Mismatch Following Supra-Annular Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. JACC. 2021.
89. **458.** Whisenant B, Kapadis S, Eleid M, et al. One-Year Outcomes of Mitral Valve-in-Valve
90. Using the SAPIEN 3 Transcatheter Heart Valve. JACC. 2020.
91. **472**. Butala NM, Makkar R, Secemsky EA, et al. Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results from the TVT Registry. Circulation. 2021 Feb 23. doi: 10.1161/CIRCULATIONAHA.120.052874.
92. **559.** Mack M, Carroll JD, Thourani V, et al. Transcatheter Mitral Valve Therapy in the United States: A Report from the STS/ACC TVT Registry. Ann Thorac Surg. 2022 Jan.
93. **561.** Makkar RR, Yoon SH, Chakravarty T, et al. Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke Among Patients at Low Surgical Risk. JAMA. 21 Sep 2021.
94. **593.** Forrest JK, Kaple RK, Tang GHL, et al. Three Generations of Self-Expanding Transcatheter Aortic Valves. J Am Coll Cardiol Intv. 2020 Jan, 13 (2) 170-179.
95. **N/A.** Mack MJ, Holmes DR Jr., et al. Rational dispersion for the introduction of transcatheter valve therapy. JAMA. 2011 Nov 16; 306(19):2149-50.

96. **N/A.** Sedrakyan A, Marinac-Dabic D, Holmes DR, et al. The international registry infrastructure for cardiovascular device evaluation and surveillance. JAMA. 2013 Jul 17;310(3):257-9.
97. **N/A.** Rumsfeld JS, Holmes DR, Stough WG, et al. Insights from the Early Experience of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol Intv. 2015.
98. **N/A.** John D. Carroll, Jeff Shuren, Tamara Syrek Jensen, John Hernandez, David Holmes, Danica Marinac-Dabic, Fred H. Edwards, Bram D. Zuckerman, Larry L. Wood, Richard E. Kuntz and Michael J. Mack. Transcatheter Valve Therapy Registry Is a Model for Medical Device Innovation and Surveillance. Health Affair. 2015; 328-334.

IN PRESS

1. **467.** Kaneko T, et al. Trends in Practice Patterns and Outcomes of Transcatheter Aortic Valve Replacement in the US and Japan: A Joint Data Harmonization Initiative of STS/ACC TVT and J-TVT. JAHA. In Press.

NCDR-wide Publications

PUBLISHED

1. **1.** Masoudi FM, Ponirakis A, Yeh RW, et al. Cardiovascular Care Facts: A Report from the NCDR - 2011. JACC. 2013;62(21):1931-1947.
2. **3.** Messenger JC, Ho KL, Young CH, et al. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: The NCDR Data Quality Program in 2012. JACC. 2012; 60(16):1484-8.
3. **4.** Masoudi FA, Ponirakis A, de Lemos JA, et al. Trends in U.S. Cardiovascular Care 2016 Report From 4 ACC National Cardiovascular Data Registries. J Am Coll Cardiol. 2017.
4. **5.** Jalbert, JJ, Nguyen, LL, Gerhard-Herman, MD, et al.; Comparative Effectiveness of Carotid Artery Stenting Versus Carotid Endarterectomy Among Medicare Beneficiaries. CIRC QO. 2016; 9:275-285.
5. **6.** Anderson HV, Weintraub WS, Radford MJ, et al. Standardized Cardiovascular Data for Clinical Research, Registries, and Patient Care a Report from the Data Standards Workgroup of the National Cardiovascular Research Infrastructure Project. A collaboration of the Duke Clinical Research Institute and the American College of Cardiology - National Cardiovascular Data Registry. JACC. 2013; 61:1835-46.
6. **8.** Malenka DJ, Bhatt DL, Bradley SM, et al. The National Cardiovascular Data Quality Program 2020 JACC State-of-the-Art Review. JACC. 2022.

IN PRESS

CARE Registry®

The Care Registry is now closed; all manuscripts have been published

PUBLISHED

1. **1.** Gruberg L, Jeremias A, Rundback JH, et al. Impact of glomerular filtration rate on clinical outcomes following carotid artery revascularization in 11,832 patients from the CARE registry. Catheter Cardiovasc Interv. 2014;84(2).
2. **2.** White CJ, Anderson HV, Brindis RG, et al. The Carotid Artery Revascularization and Endarterectomy (CARE) registry: objectives, design, and implications. Catheter Cardiovasc Interv. 2008;71(6):721-5.
3. **3.** Yeh RW, Kennedy K, Spertus JA, et al. Do post marketing surveillance studies represent real-world populations? A comparison of patient characteristics and outcomes after carotid artery stenting. Circulation. 2011;123(13):1384-90.
4. **4.** Don CW, House J, White C, et al. Carotid revascularization immediately before urgent cardiac surgery practice patterns associated with the choice of carotid artery stenting or endarterectomy: a report from the CARE (Carotid Artery Revascularization and Endarterectomy) registry. JACC Cardiovasc Interv. 2011;4(11):1200-8.
5. **5.** Anderson HV, Rosenfield KA, White CJ, et al. Clinical features and outcomes of carotid artery stenting by clinical expert consensus criteria: a report from the CARE registry. Catheter Cardiovasc Interv. 2010;75(4):519-25.
6. **7.** Rajamani K, Kennedy KF, Ruggiero NJ, et al. Outcomes of Carotid Endarterectomy in the Elderly: Report from the National Cardiovascular Data Registry. Stroke. 2013;44(4):1172-4.
7. **8.** Longmore RB, Yeh RW, Kennedy KF, et al. Clinical Referral Patterns for Carotid Artery Stenting Versus Carotid Endarterectomy: Results from the Carotid Artery Revascularization and Endarterectomy Registry. Circ Interv. 2011; 4:88-94.
8. **9.** Hynes BG, Kennedy KF, Ruggiero NJ, et al. Carotid Artery Stenting for Recurrent Carotid Artery Restenosis After Previous Ipsilateral Carotid Artery Endarterectomy or Stenting: A Report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2014;7(2):180-6.
9. **11.** Mercado N, Cohen DJ, Spertus JA, et al. Carotid artery stenting of a contralateral occlusion and in-hospital outcomes: results from the CARE (Carotid Artery Revascularization and Endarterectomy) registry. JACC Cardiovasc Interv. 2013;6(1):59-64.
10. **13.** Wayangankar SA, Abu-Fadel MS, Aronow HD, et al. Hemorrhagic and Ischemic Outcomes After Bivalirudin Versus Unfractionated Heparin During Carotid Artery Stenting: A Propensity Score Analysis From the NCDR. Circ Interv. 2013:6(2).
11. **14.** Giri J, Yeh RW, Kennedy KF, et al. Unprotected carotid artery stenting in modern practice. Catheter Cardiovasc Interv. 2014; 83:595–602.
12. **15.** Giri J, Kennedy KF, Weinberg I, et al. Comparative Effectiveness of Commonly Used Devices for Carotid Artery Stenting an NCDR Analysis (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2014;7(2):171-7.
13. **16.** Giri J, Parikh SA, Kennedy KF, et al. Proximal Versus Distal Embolic Protection for Carotid Artery Stenting: A National Cardiovascular Data Registry Analysis. JACC Cardiovasc Interv. 2015; 8:609-615.
14. **17.** Hawkins BM, Kennedy KF, Giri J, et al. Pre-procedural Risk Quantification for Carotid Stenting Using the CAS Score: A Report from the NCDR CARE Registry. JACC. 2012;60(17):1617-22.
15. **18.** Hawkins BM, Kennedy KF, Yeh RW, et al. Hospital Variation in Carotid Stenting Outcomes. JACC Cardiovasc Interv. 2015;8(6):858-863.

16. **19.** Wimmer NJ, Spertus JA, Kennedy KF, et al. Clinical Prediction Model Suitable for Assessing Hospital Quality for Patients Undergoing Carotid Endarterectomy. JAHA. 2014;3(3).
17. **20.** Wayangankar SA, Kennedy KF, Latif F, et al. Racial/Ethnic Variation in Carotid Artery Revascularization Utilization and Outcomes Analysis from the National Cardiovascular Data Registry. Stroke. 2015; 46:1525-1532.
18. **21.** Aronow HD, Kennedy KF, Wayangankar SA, et al. Prescription of Guideline-Based Medical Therapies at Discharge After Carotid Artery Stenting and Endarterectomy: An NCDR Analysis. Stroke. 2016;47(9).